BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003;36:687-696. [PMID: 12627352 DOI: 10.1086/368083] [Cited by in Crossref: 454] [Cited by in F6Publishing: 427] [Article Influence: 23.9] [Reference Citation Analysis]
Number Citing Articles
1 Si Ahmed SN, Zoulim F. Pathobiology of HBV mutants and clinical impact for treatment monitoring. Expert Review of Anti-infective Therapy 2014;7:309-20. [DOI: 10.1586/eri.09.10] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
2 Zoulim F. Emerging drugs for hepatitis B. Expert Opin Emerg Drugs 2007;12:199-217. [PMID: 17604497 DOI: 10.1517/14728214.12.2.199] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
3 Zhang YY, Hu KQ. Rethinking the pathogenesis of hepatitis B virus (HBV) infection. J Med Virol 2015;87:1989-99. [PMID: 25989114 DOI: 10.1002/jmv.24270] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
4 Takeda A, Jones J, Shepherd J, Davidson P, Price A. A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B. J Viral Hepat 2007;14:75-88. [PMID: 17244247 DOI: 10.1111/j.1365-2893.2006.00808.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
5 Delaney WE 4th, Yang H, Miller MD, Gibbs CS, Xiong S. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother 2004;48:3702-10. [PMID: 15388423 DOI: 10.1128/AAC.48.10.3702-3710.2004] [Cited by in Crossref: 61] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
6 Kanwal F, Farid M, Martin P, Chen G, Gralnek IM, Dulai GS, Spiegel BMR. Treatment Alternatives for Hepatitis B Cirrhosis: A Cost-Effectiveness Analysis. Am J Gastroenterol 2006;101:2076-89. [DOI: 10.1111/j.1572-0241.2006.00769.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 3.3] [Reference Citation Analysis]
7 Wong VW, Law MY, Hui AY, Lo AO, Li CY, Soo MT, Leung HY, Chan HL. A hospital clinic-based survey on traditional Chinese medicine usage among chronic hepatitis B patients. Complement Ther Med 2005;13:175-82. [PMID: 16150371 DOI: 10.1016/j.ctim.2005.04.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
8 Gish R, Jia JD, Locarnini S, Zoulim F. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis. 2012;12:341-353. [PMID: 22326017 DOI: 10.1016/s1473-3099(11)70314-0] [Cited by in Crossref: 98] [Cited by in F6Publishing: 39] [Article Influence: 9.8] [Reference Citation Analysis]
9 Chan HL, Hui AY, Wong VW, Chim AM, Wong M, Sung JJ. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology 2005;41:1357-64. [DOI: 10.1002/hep.20695] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 3.1] [Reference Citation Analysis]
10 Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol. 2006;44:422-431. [PMID: 16364492 DOI: 10.1016/j.jhep.2005.11.036] [Cited by in Crossref: 119] [Cited by in F6Publishing: 111] [Article Influence: 7.0] [Reference Citation Analysis]
11 Pai SB, Bozdayi AM, Pai RB, Beker T, Sarioglu M, Turkyilmaz AR, Grier J, Yurdaydin C, Schinazi RF. Emergence of a novel mutation in the FLLA region of hepatitis B virus during lamivudine therapy. Antimicrob Agents Chemother 2005;49:2618-24. [PMID: 15980328 DOI: 10.1128/AAC.49.7.2618-2624.2005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
12 Ahn SH, Heo J, Park JY, Woo HY, Lee HJ, Tak WY, Um SH, Yoon KT, Park SY, Kim CW, Kim HH, Han KH, Cho M. A 96-week randomized trial of switching to entecavir in patients who achieved virological suppression on lamivudine therapy. J Gastroenterol Hepatol 2016;31:865-71. [PMID: 26572068 DOI: 10.1111/jgh.13231] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
13 Deng L, Tang H. Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites. Hepatol Res. 2011;41:1017-1024. [PMID: 21917087 DOI: 10.1111/j.1872-034x.2011.00873.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
14 Karlas T, Hartmann J, Weimann A, Maier M, Bartels M, Jonas S, Mössner J, Berg T, Tillmann HL, Wiegand J. Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only. Transpl Infect Dis. 2011;13:299-302. [PMID: 21159112 DOI: 10.1111/j.1399-3062.2010.00591.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
15 Ohkawa K, Takehara T, Kato M, Kanada A, Deguchi M, Kagita M, Hikita H, Sasakawa A, Kohga K, Uemura A, Sakamori R, Yamaguchi S, Miyagi T, Ishida H, Tatsumi T, Hayashi N. Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis. J Med Virol 2009;81:798-806. [DOI: 10.1002/jmv.21348] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
16 Zhang Q, Liao Y, Cai B, Li Y, Li L, Zhang J, An Y, Wang L. Incidence of natural resistance mutations in naïve chronic hepatitis B patients: A systematic review and meta-analysis: Hepatitis B virus natural mutation rate. J Gastroenterol Hepatol 2015;30:252-61. [DOI: 10.1111/jgh.12831] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
17 Chen LP, Zhao J, Du Y, Han YF, Su T, Zhang HW, Cao GW. Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World J Virol 2012; 1(6): 174-183 [PMID: 24175223 DOI: 10.5501/wjv.v1.i6.174] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
18 Sherman M. Predicting survival in hepatitis B. Gut. 2005;54:1521-1523. [PMID: 16227355 DOI: 10.1136/gut.2005.071332] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
19 Litwin S, Toll E, Jilbert AR, Mason WS. The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: theoretical considerations. J Clin Virol. 2005;34 Suppl 1:S96-S107. [PMID: 16461233 DOI: 10.1016/s1386-6532(05)80018-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
20 Larrat S, Hilleret MN, Germi R, Lupo J, Nicod S, Zarski JP, Seigneurin JM, Morand P. Sustained virological and biochemical responses to lamivudine and adefovir dipivoxil combination in a chronic hepatitis B infection despite mutations conferring resistance to both drugs. Comp Hepatol 2008;7:3. [PMID: 18336716 DOI: 10.1186/1476-5926-7-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
21 Seifer M, Patty A, Serra I, Li B, Standring DN. Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir. Antiviral Res. 2009;81:147-155. [PMID: 19028525 DOI: 10.1016/j.antiviral.2008.10.008] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 3.0] [Reference Citation Analysis]
22 Lee YB, Lee JH, Choi WM, Cho YY, Yoo JJ, Lee M, Lee DH, Cho Y, Yu SJ, Kim YJ, Yoon JH, Kim CY, Lee HS. Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection. Antimicrob Agents Chemother 2013;57:6325-32. [PMID: 24100506 DOI: 10.1128/AAC.01742-13] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
23 Lin CC, Bair MJ, Chen CJ, Lee KH, Chen MJ, Liu CY, Chang CW, Hu KC, Liou TC, Lin SC, Wang HY, Chu CH, Shih SC, Wang TE. Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients. Kaohsiung J Med Sci 2016;32:10-5. [PMID: 26853169 DOI: 10.1016/j.kjms.2015.11.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
24 Shin HS, Kim SU, Park JY, Kim DY, Han KH, Chon CY, Baatarkhuu O, Ahn SH. Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2012;27:1528-34. [PMID: 22497450 DOI: 10.1111/j.1440-1746.2012.07145.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
25 Zoulim F. [Current data on the treatment of chronic hepatitis B]. Presse Med 2008;37:287-93. [PMID: 18042341 DOI: 10.1016/j.lpm.2007.06.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Ye XG, Su QM. Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: Meta-analysis. World J Gastroenterol 2013; 19(39): 6665-6678 [PMID: 24151397 DOI: 10.3748/wjg.v19.i39.6665] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
27 Chotiyaputta W, Lok ASF. Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol 2009;6:453-62. [DOI: 10.1038/nrgastro.2009.107] [Cited by in Crossref: 109] [Cited by in F6Publishing: 102] [Article Influence: 8.4] [Reference Citation Analysis]
28 Yang JH, Zhang H, Chen XB, Chen G, Wang X. Relationship between hepatocellular carcinoma and hepatitis B virus genotype with spontaneous YMDD mutations. World J Gastroenterol 2013; 19(24): 3861-3865 [PMID: 23840126 DOI: 10.3748/wjg.v19.i24.3861] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
29 Lee HJ, Eun JR, Lee CH, Hwang JS, Suh JI, Kim BS, Jang BK. [Long-term clevudine therapy in nucleos(t)ide-naïve and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases]. Korean J Hepatol. 2009;15:179-192. [PMID: 19581770 DOI: 10.3350/kjhep.2009.15.2.179] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
30 Akbar SM, Hiasa Y, Mishiro S, Onji M. Treatment of hepatitis B virus-infected patients: utility of therapeutic recommendations in developing countries. Expert Opin Pharmacother 2009;10:1605-14. [PMID: 19496738 DOI: 10.1517/14656560903005579] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
31 Montagnani M, Giandinoto M, Lisotti A, Galli S, Azzaroli F, Buonfiglioli F, Turco L, Aldini R, Mazzella G. High dose lamivudine in HBV-related cirrhotic patients with unsatisfactory response after adefovir add-on. Dig Dis Sci 2012;57:561-7. [PMID: 21881973 DOI: 10.1007/s10620-011-1873-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
32 Wong VW, Chan HL, Wong ML, Tam JS, Leung NW. Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants. Aliment Pharmacol Ther. 2004;19:323-329. [PMID: 14984379 DOI: 10.1111/j.1365-2036.2004.01845.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
33 Yuen MF, Fong DY, Wong DK, Yuen JC, Fung J, Lai CL. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology. 2007;46:1695-1703. [PMID: 18027877 DOI: 10.1002/hep.21939] [Cited by in Crossref: 81] [Cited by in F6Publishing: 81] [Article Influence: 5.8] [Reference Citation Analysis]
34 Dakin H, Bentley A, Dusheiko G. Cost–Utility Analysis of Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis B. Value in Health 2010;13:922-33. [DOI: 10.1111/j.1524-4733.2010.00782.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
35 Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV;  GLOBE Study Group. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486-495. [PMID: 19027013 DOI: 10.1053/j.gastro.2008.10.026] [Cited by in Crossref: 412] [Cited by in F6Publishing: 394] [Article Influence: 29.4] [Reference Citation Analysis]
36 Dando TM, Plosker GL. Adefovir Dipivoxil: A Review of its Use in Chronic Hepatitis B. Drugs 2003;63:2215-34. [DOI: 10.2165/00003495-200363200-00007] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 4.0] [Reference Citation Analysis]
37 Qiu L, Chen L, Chen K. Antihepatitis B therapy: a review of current medications and novel small molecule inhibitors. Fundam Clin Pharmacol 2014;28:364-81. [DOI: 10.1111/fcp.12053] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
38 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 2019;25:93-159. [PMID: 31185710 DOI: 10.3350/cmh.2019.1002] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 21.3] [Reference Citation Analysis]
39 Wong F, Pai R, Schalkwyk JV, Yoshida EM. Hepatitis B in pregnancy: a concise review of neonatal vertical transmission and antiviral prophylaxis. Annals of Hepatology 2014;13:187-95. [DOI: 10.1016/s1665-2681(19)30881-6] [Cited by in Crossref: 20] [Article Influence: 2.5] [Reference Citation Analysis]
40 Tong S, Revill P. Overview of hepatitis B viral replication and genetic variability. J Hepatol 2016;64:S4-S16. [PMID: 27084035 DOI: 10.1016/j.jhep.2016.01.027] [Cited by in Crossref: 186] [Cited by in F6Publishing: 184] [Article Influence: 37.2] [Reference Citation Analysis]
41 Chen CH, Wang JH, Lu SN, Hu TH, Hung CH, Chang MH, Changchien CS, Lee CM. Characteristics of adefovir resistance in patients with or without lamivudine-resistant hepatitis B virus treated with adefovir: a 4-year experience. Liver Int. 2011;31:206-214. [PMID: 21143368 DOI: 10.1111/j.1478-3231.2010.02416.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
42 Wu F, Wu MJ, Zhuge XL, Zhu SM, Zhu B. Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in Chinese patients with chronic hepatitis B during lamivudine treatment. Hepatobiliary Pancreat Dis Int 2012;11:172-6. [PMID: 22484586 DOI: 10.1016/s1499-3872(12)60144-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
43 Jiang L, Yan LN. Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation. World J Gastroenterol 2010; 16(20): 2468-2475 [PMID: 20503446 DOI: 10.3748/wjg.v16.i20.2468] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
44 Fournier C, Zoulim F. Antiviral therapy of chronic hepatitis B: prevention of drug resistance. Clin Liver Dis. 2007;11:869-892, ix. [PMID: 17981233 DOI: 10.1016/j.cld.2007.08.013] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
45 van Zonneveld M, Zondervan PE, Cakaloglu Y, Simon C, Akarca US, So TM, Flink HJ, de Man RA, Schalm SW, Janssen HL; HBV 99-01 Study Group. Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine. Liver Int. 2006;26:399-405. [PMID: 16629642 DOI: 10.1111/j.1478-3231.2006.01257.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 1.7] [Reference Citation Analysis]
46 Day SL, Odem-Davis K, Mandaliya KN, Jerome KR, Cook L, Masese LN, Scott J, Kim HN, Graham SM, McClelland RS. Prevalence, clinical and virologic outcomes of hepatitis B virus co-infection in HIV-1 positive Kenyan women on antiretroviral therapy. PLoS One. 2013;8:e59346. [PMID: 23527168 DOI: 10.1371/journal.pone.0059346] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
47 Lee YB, Lee JH, Choi WM, Cho YY, Yoo JJ, Lee M, Lee DH, Cho Y, Yu SJ, Kim YJ. Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection. Antimicrob Agents Chemother. 2013;57:6325-6332. [PMID: 24100506 DOI: 10.1128/aac.01742-13aac.01742-13] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Lee YB, Lee JH, Lee DH, Cho H, Ahn H, Choi WM, Cho YY, Lee M, Yoo JJ, Cho Y. Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains. Antimicrob Agents Chemother. 2014;58:6710-6716. [PMID: 25155601 DOI: 10.1128/AAC.03845-14] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
49 Yeh CT, Chen T, Hsu CW, Chen YC, Lai MW, Liang KH, Chen TC. Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B. BMC Cancer. 2011;11:398. [PMID: 21933446 DOI: 10.1186/1471-2407-11-398] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
50 Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, Fang J, Yu CF, Zhang S, Mazzucco CE, Eggers B, Hsu M, Plym MJ, Poundstone P, Yang J, Colonno RJ. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007;51:902-11. [PMID: 17178796 DOI: 10.1128/AAC.00833-06] [Cited by in Crossref: 172] [Cited by in F6Publishing: 50] [Article Influence: 10.8] [Reference Citation Analysis]
51 Nishida T, Kobashi H, Fujioka S, Fujio K, Takaguchi K, Ikeda H, Kawaguchi M, Ando M, Araki Y, Higashi T. A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis. J Gastroenterol Hepatol. 2008;23:794-803. [PMID: 18086120 DOI: 10.1111/j.1440-1746.2007.05240.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
52 But DY, Yuen MF, Fung J, Lai CL. Safety evaluation of telbivudine. Expert Opin Drug Saf. 2010;9:821-829. [PMID: 20662545 DOI: 10.1517/14740338.2010.507190] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
53 Mello FC, Fernandes CA, Gomes Sde A. Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes. Mem Inst Oswaldo Cruz. 2012;107:317-325. [PMID: 22510826 DOI: 10.1590/S0074-02762012000300005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
54 Yun H, Kim T, Kim T, Choi HS, Bae S. Anti-TNF-α Therapy in Rheumatic Diseases with Chronic Hepatitis B Virus Infection. J Korean Rheum Assoc 2007;14:242. [DOI: 10.4078/jkra.2007.14.3.242] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
55 Wong VW, Chan HL. Severe acute exacerbation of chronic hepatitis B: A unique presentation of a common disease. J Gastroenterol Hepatol. 2009;24:1179-1186. [PMID: 19682192 DOI: 10.1111/j.1440-1746.2009.05924.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 3.8] [Reference Citation Analysis]
56 Lee HW, Park JY, Lee JW, Yoon KT, Kim CW, Park H, Kim YS, Paik SK, Lee JI, Kim BK, Han KH, Ahn SH. Long-term Efficacy of Tenofovir Disoproxil Fumarate Monotherapy for Multidrug-Resistant Chronic HBV infection. Clin Gastroenterol Hepatol 2019;17:1348-1355.e2. [PMID: 30613003 DOI: 10.1016/j.cgh.2018.10.037] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
57 Poortahmasebi V, Malekzadeh R, Montazeri G, Fakhari E, Norouzi M, Khamseh A, Mahmoodi Karkhaneh M, Tavakoli A, Jazayeri SM. Lamivudine Resistance and Precore Variants in Iranian Patients With Chronic Hepatitis B: Correlation With Virological and Clinical Features. Jundishapur J Microbiol 2015;8:e20262. [PMID: 26487918 DOI: 10.5812/jjm.20262] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
58 Zoulim F, Locarnini S. Management of treatment failure in chronic hepatitis B. J Hepatol. 2012;56 Suppl 1:S112-S122. [PMID: 22300461 DOI: 10.1016/s0168-8278(12)60012-9] [Cited by in Crossref: 90] [Cited by in F6Publishing: 41] [Article Influence: 9.0] [Reference Citation Analysis]
59 Zoulim F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int. 2011;31 Suppl 1:111-116. [PMID: 21205147 DOI: 10.1111/j.1478-3231.2010.02399.x.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
60 Locarnini S, Bowden S. Drug Resistance in Antiviral Therapy. Clinics in Liver Disease 2010;14:439-59. [DOI: 10.1016/j.cld.2010.05.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
61 Jacobson IM. Therapeutic options for chronic hepatitis B: considerations and controversies. Am J Gastroenterol 2006;101 Suppl 1:S13-8. [PMID: 16448447 DOI: 10.1111/j.1572-0241.2006.00477.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
62 Sherman M. Personal view: the management of chronic hepatitis B infection. Aliment Pharmacol Ther 2006;23:857-69. [DOI: 10.1111/j.1365-2036.2006.02840.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
63 Egwim C, Botero R. Is Hepatitis B Immunoglobulin Prophylaxis Needed for Liver Transplantation in the Era of New Antivirals? Transplantation Proceedings 2005;37:2200-4. [DOI: 10.1016/j.transproceed.2005.03.109] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
64 Chaabane NB, Loghmari H, Melki W, Hellara O, Safer L, Bdioui F, Saffar H. [Chronic viral hepatitis and kidney failure]. Presse Med 2008;37:665-78. [PMID: 18291615 DOI: 10.1016/j.lpm.2007.10.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
65 Kurashige N, Hiramatsu N, Ohkawa K, Oze T, Inoue Y, Kurokawa M, Yakushijin T, Igura T, Kiso S, Kanto T, Takehara T, Tamura S, Kasahara A, Oshita M, Hijioka T, Katayama K, Yoshihara H, Hayashi E, Imai Y, Kato M, Hayashi N. Initial viral response is the most powerful predictor of the emergence of YMDD mutant virus in chronic hepatitis B patients treated with lamivudine. Hepatology Research 2008;38:450-6. [DOI: 10.1111/j.1872-034x.2007.00292.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
66 Murata M, Furusyo N, Unno M, Ogawa E, Toyoda K, Taniai H, Ohnishi H, Hayashi J. Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients. World J Gastroenterol 2011; 17(24): 2945-2952 [PMID: 21734806 DOI: 10.3748/wjg.v17.i24.2945] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
67 Ko SY, Kim BK, Kwon SY, Kim KH, Kim JH, Choe WH, Lee CH. Clonal evolution of hepatitis B virus polymerase gene mutations during lamivudine-adefovir combination treatment. World J Gastroenterol 2012; 18(44): 6437-6446 [PMID: 23197889 DOI: 10.3748/wjg.v18.i44.6437] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
68 Zhu Y, Curtis M, Borroto-esoda K. HBV DNA replication mediated by cloned patient HBV reverse transcriptase genes from HBV genotypes A–H and its use in antiviral phenotyping assays. Journal of Virological Methods 2011;173:340-6. [DOI: 10.1016/j.jviromet.2011.03.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
69 Li H, Yan L, Shi Y, Lv D, Shang J, Bai L, Tang H. Hepatitis B Virus Infection: Overview. Adv Exp Med Biol 2020;1179:1-16. [PMID: 31741331 DOI: 10.1007/978-981-13-9151-4_1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
70 Strasfeld L, Chou S. Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin North Am. 2010;24:809-833. [PMID: 20674805 DOI: 10.1016/j.idc.2010.07.001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
71 Fisher A, Musini VM, Bassett K; Cochrane Hepato-Biliary Group. Antiviral treatments for lamivudine-resistant chronic hepatitis B adult patients. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd008178] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
72 Zhang Y, Zhang Y, Kang Y, Wang J, Liu H, Zhu H, Qin Y, Mao R, Lin X, Lu M, Zhang J. Generation of a human hepatoma cell line supporting efficient replication of a lamivudine resistant hepatitis B virus. Journal of Virological Methods 2014;201:51-6. [DOI: 10.1016/j.jviromet.2014.02.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
73 Valsamakis A. Molecular testing in the diagnosis and management of chronic hepatitis B. Clin Microbiol Rev. 2007;20:426-439, table of contents. [PMID: 17630333 DOI: 10.1128/cmr.00009-07] [Cited by in Crossref: 86] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
74 Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, Chung YH, Lee YS, Yoo W, Kim SO. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology. 2006;43:1385-1391. [PMID: 16729316 DOI: 10.1002/hep.21189] [Cited by in Crossref: 239] [Cited by in F6Publishing: 214] [Article Influence: 14.9] [Reference Citation Analysis]
75 Zoulim F. Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance? Antivir Chem Chemother. 2004;15:299-305. [PMID: 15646643 DOI: 10.1177/095632020401500602] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 2.3] [Reference Citation Analysis]
76 Russo FP, Rodríguez-Castro K, Scribano L, Gottardo G, Vanin V, Farinati F. Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease. World J Hepatol 2015; 7(8): 1097-1104 [PMID: 26052398 DOI: 10.4254/wjh.v7.i8.1097] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
77 Choi J, Lim Y. Nucleos(t)ide Therapy and Long-Term Outcomes. In: Kao J, Chen D, editors. Hepatitis B Virus and Liver Disease. Singapore: Springer; 2018. pp. 193-217. [DOI: 10.1007/978-981-10-4843-2_11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
78 Poynard T, Zoulim F, Ratziu V, Degos F, Imbert-Bismut F, Deny P, Landais P, El Hasnaoui A, Slama A, Blin P. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol. 2005;100:1970-1980. [PMID: 16128941 DOI: 10.1111/j.1572-0241.2005.41957.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 4.7] [Reference Citation Analysis]
79 Leung N. Lamivudine for chronic hepatitis B. Expert Rev Anti Infect Ther. 2004;2:173-180. [PMID: 15482184 DOI: 10.1586/14787210.2.2.173] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
80 Cai S, Yu T, Jiang Y, Zhang Y, Lv F, Peng J. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result. Clin Exp Med 2016;16:429-36. [PMID: 26164128 DOI: 10.1007/s10238-015-0373-2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
81 Song BC. Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination? Clin Mol Hepatol 2016;22:439-42. [PMID: 28081595 DOI: 10.3350/cmh.2016.0108] [Reference Citation Analysis]
82 Xu B, Huang Z, Liu C, Cai Z, Pan W, Cao P, Hao X, Liang G. Synthesis and anti-hepatitis B virus activities of Matijing-Su derivatives. Bioorganic & Medicinal Chemistry 2009;17:3118-25. [DOI: 10.1016/j.bmc.2009.03.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
83 Yao G, Chen C, Lu W, Ren H, Tan D, Wang Y, Xu D, Jiang Z, Liu J, Xu D. Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China. Hepatol Int. 2007;1:365-372. [PMID: 19669331 DOI: 10.1007/s12072-007-9009-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
84 Dienstag JL. The value and limitations of long-term nucleoside antiviral therapy in chronic hepatitis B. Journal of Hepatology 2005;42:158-62. [DOI: 10.1016/j.jhep.2004.12.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
85 Lee YB, Lee JH, Lee DH, Cho H, Ahn H, Choi WM, Cho YY, Lee M, Yoo JJ, Cho Y. Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains. Antimicrob Agents Chemother. 2014;58:6710-6716. [PMID: 25155601 DOI: 10.1128/aac.03845-14aac.03845-14] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
86 Han SB. Telbivudine: a new nucleoside analogue for the treatment of chronic hepatitis B. Expert Opinion on Investigational Drugs 2005;14:511-9. [DOI: 10.1517/13543784.14.4.511] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
87 De Clercq E. Current treatment of hepatitis B virus infections: Current treatment of HBV Infections. Rev Med Virol 2015;25:354-65. [DOI: 10.1002/rmv.1849] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
88 Matthews SJ. Entecavir for the treatment of chronic hepatitis B virus infection. Clin Ther. 2006;28:184-203. [PMID: 16678641 DOI: 10.1016/j.clinthera.2006.02.012] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 3.1] [Reference Citation Analysis]
89 Lu D, Liu F, Xing W, Tong X, Wang L, Wang Y, Zeng L, Feng C, Yang L, Zuo J, Hu Y. Optimization and Synthesis of Pyridazinone Derivatives as Novel Inhibitors of Hepatitis B Virus by Inducing Genome-free Capsid Formation. ACS Infect Dis 2017;3:199-205. [DOI: 10.1021/acsinfecdis.6b00159] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
90 Dienstag J, Easley C, Kirkpatrick P. Telbivudine. Nat Rev Drug Discov 2007;6:267-8. [DOI: 10.1038/nrd2295] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
91 van der Poorten D, Prakoso E, Khoo TL, Ngu MC, McCaughan GW, Strasser SI, Lee AU. Combination adefovir-lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B. J Gastroenterol Hepatol. 2007;22:1500-1505. [PMID: 17683493 DOI: 10.1111/j.1440-1746.2007.05093.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
92 Colagrossi L, Hermans LE, Salpini R, Di Carlo D, Pas SD, Alvarez M, Ben-Ari Z, Boland G, Bruzzone B, Coppola N, Seguin-Devaux C, Dyda T, Garcia F, Kaiser R, Köse S, Krarup H, Lazarevic I, Lunar MM, Maylin S, Micheli V, Mor O, Paraschiv S, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Simon F, Stanojevic M, Stene-Johansen K, Tihic N, Trimoulet P, Verheyen J, Vince A, Lepej SZ, Weis N, Yalcinkaya T, Boucher CAB, Wensing AMJ, Perno CF, Svicher V; HEPVIR working group of the European Society for translational antiviral research (ESAR). Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe. BMC Infect Dis 2018;18:251. [PMID: 29859062 DOI: 10.1186/s12879-018-3161-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
93 Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carrouée-Durantel S, Villeneuve JP, Trépo C, Zoulim F. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology. 2005;41:1391-1398. [PMID: 15915463 DOI: 10.1002/hep.20723] [Cited by in Crossref: 201] [Cited by in F6Publishing: 185] [Article Influence: 11.8] [Reference Citation Analysis]
94 Margeridon-Thermet S, Shulman NS, Ahmed A, Shahriar R, Liu T, Wang C, Holmes SP, Babrzadeh F, Gharizadeh B, Hanczaruk B. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis. 2009;199:1275-1285. [PMID: 19301976 DOI: 10.1086/597808] [Cited by in Crossref: 160] [Cited by in F6Publishing: 156] [Article Influence: 12.3] [Reference Citation Analysis]
95 Haché C, Villeneuve JP. Lamivudine treatment in patients with chronic hepatitis B and cirrhosis. Expert Opin Pharmacother. 2006;7:1835-1843. [PMID: 16925509 DOI: 10.1517/14656566.7.13.1835] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
96 Sung JJ, Wong M, Bowden S, Liew C, Hui AY, Wong VW, Leung NW, Locarnini S, Chan HL. Intrahepatic Hepatitis B Virus Covalently Closed Circular DNA Can Be a Predictor of Sustained Response to Therapy. Gastroenterology 2005;128:1890-7. [DOI: 10.1053/j.gastro.2005.03.009] [Cited by in Crossref: 160] [Cited by in F6Publishing: 154] [Article Influence: 9.4] [Reference Citation Analysis]
97 Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int. 2008;2:147-151. [PMID: 19669299 DOI: 10.1007/s12072-008-9048-3] [Cited by in Crossref: 99] [Cited by in F6Publishing: 99] [Article Influence: 7.1] [Reference Citation Analysis]
98 Toyama T, Ishida H, Ishibashi H, Yatsuhashi H, Nakamuta M, Shimada M, Ohta H, Satoh T, Kato M, Hijioka T, Takano H, Komeda T, Yagura M, Mano H, Watanabe Y, Kobayashi M, Mita E. Long-term outcomes of add-on adefovir dipivoxil therapy to ongoing lamivudine in patients with lamivudine-resistant chronic hepatitis B: Long-term outcomes of add-on ADV therapy. Hepatology Research 2012;42:1168-74. [DOI: 10.1111/j.1872-034x.2012.01038.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
99 Kim KM, Choi WB, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine-resistant hepatitis B virus. J Korean Med Sci. 2005;20:821-828. [PMID: 16224157 DOI: 10.3346/jkms.2005.20.5.821] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
100 Sáez-López A, Agüero-Balbín J. [Hepatitis B and C virus antiviral resistance]. Enferm Infecc Microbiol Clin 2006;24:576-84. [PMID: 17125678 DOI: 10.1157/13093879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
101 Toy M, Hutton DW, So SK. Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China. PLoS One 2015;10:e0139876. [PMID: 26536626 DOI: 10.1371/journal.pone.0139876] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
102 Abdel-Hady M, Kelly D. Chronic hepatitis B in children and adolescents: epidemiology and management. Paediatr Drugs 2013;15:311-7. [PMID: 23529864 DOI: 10.1007/s40272-013-0010-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
103 Mauss S, Wedemeyer H. Treatment of chronic hepatitis B and the implications of viral resistance to therapy. Expert Review of Anti-infective Therapy 2014;6:191-9. [DOI: 10.1586/14787210.6.2.191] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
104 Lacey LF, Gane E. The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore. J Viral Hepat 2007;14:751-66. [PMID: 17927611 DOI: 10.1111/j.1365-2893.2007.00865.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
105 Chen EQ, Lei BJ, Tang H. Clinical application and research progress in hepatitis B virus quasispecies. Shijie Huaren Xiaohua Zazhi 2008; 16(10): 1086-1091 [DOI: 10.11569/wcjd.v16.i10.1086] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
106 Du Y, Su T, Ding Y, Cao G. Effects of antiviral therapy on the recurrence of hepatocellular carcinoma after curative resection or liver transplantation. Hepat Mon. 2012;12:e6031. [PMID: 23166535 DOI: 10.5812/hepatmon.6031] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
107 Shapiro F, Smeets V, Donck JC, Ottevaere W. Innogenetics NV. Per Med 2005;2:127-33. [PMID: 29788587 DOI: 10.1517/17410541.2.2.127] [Reference Citation Analysis]
108 He M, Wu Y, Wang M, Chen W, Yuan W, Jiang J. The Clinical Value of Oxymatrine in Preventing Lamivudine Induced YMDD Mutation: A Meta-Analysis. Evid Based Complement Alternat Med 2015;2015:971616. [PMID: 26508988 DOI: 10.1155/2015/971616] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
109 Motavaf M, Alavian SM. RNA interference: a promising approach for the treatment of viral hepatitis. Hepat Mon. 2012;12:7-8. [PMID: 22451837 DOI: 10.5812/kowsar.1735143X.812] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
110 Wang Y, Liu S, Chen YU, Zheng S, Zhou LI, Lu F, Duan Z. Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B. Exp Ther Med. 2016;11:2293-2299. [PMID: 27313669 DOI: 10.3892/etm.2016.3230] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
111 Guo X, Wu J, Wei F, Ouyang Y, Li Q, Liu K, Wang Y, Zhang Y, Chen D. Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: A retrospective study. Int J Antimicrob Agents 2018;52:201-9. [PMID: 29654894 DOI: 10.1016/j.ijantimicag.2018.04.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
112 Hige S, Yamamoto Y, Yoshida S, Kobayashi T, Horimoto H, Yamamoto K, Sho T, Natsuizaka M, Nakanishi M, Chuma M, Asaka M. Sensitive assay for quantification of hepatitis B virus mutants by use of a minor groove binder probe and peptide nucleic acids. J Clin Microbiol 2010;48:4487-94. [PMID: 20926703 DOI: 10.1128/JCM.00731-10] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
113 Zhang F, Wang G. A review of non-nucleoside anti-hepatitis B virus agents. Eur J Med Chem 2014;75:267-81. [PMID: 24549242 DOI: 10.1016/j.ejmech.2014.01.046] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
114 Sharon A, Chu CK. Understanding the molecular basis of HBV drug resistance by molecular modeling. Antiviral Res 2008;80:339-53. [PMID: 18765256 DOI: 10.1016/j.antiviral.2008.07.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
115 Buti M, Jardi R, Rodriguez-frias F, Valdes A, Schaper M, Esteban R, Guardia J. Changes in different regions of hepatitis B virus gene in hepatitis B 'e' antigen-negative patients with chronic hepatitis B: the effect of long-term lamivudine therapy. Aliment Pharmacol Ther 2005;21:1349-56. [DOI: 10.1111/j.1365-2036.2005.02503.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
116 Liaw Y, Leung N, Guan R, Lau GK, Merican I, Mccaughan G, Gane E, Kao J, Omata M; for the Asian-Pacific consensus update working party on chronic hepatitis B. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005;25:472-89. [DOI: 10.1111/j.1478-3231.2005.01134.x] [Cited by in Crossref: 239] [Cited by in F6Publishing: 236] [Article Influence: 14.1] [Reference Citation Analysis]
117 Kwon SY, Park YK, Ahn SH, Cho ES, Choe WH, Lee CH, Kim BK, Ko SY, Choi HS, Park ES. Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients. J Virol. 2010;84:4494-4503. [PMID: 20164224 DOI: 10.1128/jvi.02066-09] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
118 Angus PW, Patterson SJ. Liver transplantation for hepatitis B: what is the best hepatitis B immune globulin/antiviral regimen? Liver Transpl. 2008;14 Suppl 2:S15-S22. [PMID: 18825721 DOI: 10.1002/lt.21614] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
119 Kim JH, Park YK, Park ES, Kim KH. Molecular diagnosis and treatment of drug-resistant hepatitis B virus. World J Gastroenterol 2014; 20(19): 5708-5720 [PMID: 24914332 DOI: 10.3748/wjg.v20.i19.5708] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
120 Salpini R, Alteri C, Cento V, Pollicita M, Micheli V, Gubertini G, De Sanctis G, Visca M, Romano S, Sarrecchia C, Andreoni M, Angelico M, Parruti G, Svicher V, Perno C. Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. J Med Virol 2013;85:996-1004. [DOI: 10.1002/jmv.23567] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
121 Locarnini S. Relevance of HBV mutations in severity and progression of chronic hepatitis B. J Gastroenterol Hepatol 2004;19:S108-12. [DOI: 10.1111/j.1440-1746.2004.03655.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
122 Cho SW, Cho YJ, Cheong JY, Lee MH, Jeon SJ, Lee YC, Lim SG, Kang CJ. [Add on lamivudine to adefovir monotherapy for the treatment of lamivudine-resistant chronic hepatitis B patients]. Korean J Gastroenterol 2010;56:83-9. [PMID: 20729619 DOI: 10.4166/kjg.2010.56.2.83] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
123 Leemans WF, Ter Borg MJ, de Man RA. Review article: Success and failure of nucleoside and nucleotide analogues in chronic hepatitis B. Aliment Pharmacol Ther 2007;26 Suppl 2:171-82. [PMID: 18081660 DOI: 10.1111/j.1365-2036.2007.03481.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
124 Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol. 2004;2:266-272. [PMID: 15017612 DOI: 10.1016/s1542-3565(04)00017-5] [Cited by in Crossref: 89] [Cited by in F6Publishing: 23] [Article Influence: 4.9] [Reference Citation Analysis]
125 Niesters HG, Zoulim F, Pichoud C, Buti M, Shapiro F, D'Heuvaert N, Celis L, Doutreloigne J, Sablon E. Validation of the INNO-LiPA HBV DR assay (version 2) in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatment. Antimicrob Agents Chemother 2010;54:1283-9. [PMID: 20065049 DOI: 10.1128/AAC.00970-09] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
126 Sablon E, Shapiro F, Zoulim F. Early detection of hepatitis B drug resistance: implications for patient management. Expert Rev Mol Diagn 2003;3:535-47. [PMID: 14510175 DOI: 10.1586/14737159.3.5.535] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
127 Villet S, Pichoud C, Villeneuve JP, Trépo C, Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology. 2006;131:1253-1261. [PMID: 17030194 DOI: 10.1053/j.gastro.2006.08.013] [Cited by in Crossref: 125] [Cited by in F6Publishing: 120] [Article Influence: 7.8] [Reference Citation Analysis]
128 Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA, Flaherty JF, Massetto B. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2014;146:980-988. [PMID: 24368224 DOI: 10.1053/j.gastro.2013.12.028] [Cited by in Crossref: 118] [Cited by in F6Publishing: 108] [Article Influence: 13.1] [Reference Citation Analysis]
129 Mahabadi M, Alavian SM, Norouzi M, Keyvani H, Mahmoudi M, Jazayeri SM. Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B. Electron Physician 2016;8:2466-74. [PMID: 27504160 DOI: 10.19082/2466] [Reference Citation Analysis]
130 Seo YS, Kim JH, Yeon JE, Park JJ, Kim JS, Byun KS, Bak YT, Lee CH. Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance. World J Gastroenterol 2007; 13(30): 4072-4079 [PMID: 17696224 DOI: 10.3748/wjg.v13.i30.4072] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
131 Pilmore HL, Gane EJ. Hepatitis B-positive donors in renal transplantation: increasing the deceased donor pool. Transplantation. 2012;94:205-210. [PMID: 22430067 DOI: 10.1097/tp.0b013e31824e3db4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 5] [Article Influence: 2.9] [Reference Citation Analysis]
132 Szmaragd C, Nichols RA, Balloux F. A novel approach to characterise pathogen candidate genetic polymorphisms involved in clinical outcome. Infect Genet Evol 2006;6:38-45. [PMID: 16376839 DOI: 10.1016/j.meegid.2005.01.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
133 Liu F, Wang X, Wei F, Hu H, Zhang D, Hu P, Ren H. Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysis. Virol J. 2014;11:59. [PMID: 24673792 DOI: 10.1186/1743-422x-11-59] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
134 Fasano M, Lampertico P, Marzano A, Di Marco V, Niro GA, Brancaccio G, Marengo A, Scotto G, Brunetto MR, Gaeta GB, Rizzetto M, Angarano G, Santantonio T. HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. J Hepatol 2012;56:1254-8. [PMID: 22343167 DOI: 10.1016/j.jhep.2012.01.022] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
135 Zoulim F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int. 2011;31 Suppl 1:111-116. [PMID: 21205147 DOI: 10.1111/j.1478-3231.2010.02399.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 7.1] [Reference Citation Analysis]
136 Motavaf M, Motavaf M, Alavian SM, Alavian SM. RNA Interference: A Promising Approach for the Treatment of Viral Hepatitis. Hepat Mon 2012;12:7-8. [DOI: 10.5812/hepatmon.4294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
137 Chinese Society of Hepatology, Chinese Medical Association and Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline on prevention and treatment of chronic hepatitis B in China (2005): . Chinese Medical Journal 2007;120:2159-73. [DOI: 10.1097/00029330-200712020-00002] [Cited by in Crossref: 81] [Cited by in F6Publishing: 43] [Article Influence: 5.4] [Reference Citation Analysis]
138 Chan HL, Wong VW, Tse CH, Chim AM, Chan HY, Wong GL, Sung JJ. Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. Aliment Pharmacol Ther. 2007;25:891-898. [PMID: 17402992 DOI: 10.1111/j.1365-2036.2007.03272.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.0] [Reference Citation Analysis]
139 Zhang CH, Xu GL, Jia WD, Li JS, Ma JL, Ge YS. Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a meta-analysis of randomized controlled trials. Int J Cancer. 2011;129:1254-1264. [PMID: 21710498 DOI: 10.1002/ijc.25767] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.5] [Reference Citation Analysis]
140 Buti M, Casado MA, Calleja JL, Salmeron J, Aguilar J, Rueda M, Esteban R. Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B. Aliment Pharmacol Ther 2006;23:409-19. [DOI: 10.1111/j.1365-2036.2006.02767.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
141 Coffin CS, Fung SK, Alvarez F, Cooper CL, Doucette KE, Fournier C, Kelly E, Ko HH, Ma MM, Martin SR, Osiowy C, Ramji A, Tam E, Villeneuve JP. Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada. CanLivJ 2018;1:156-217. [DOI: 10.3138/canlivj.2018-0008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 5.8] [Reference Citation Analysis]
142 Maklad S, Reyad EM, William EA, Abouzeid A. Efficacy and Safety of Entecavir 0. 5 mg in Treating Naive Chronic Hepatitis B Virus Patients in Egypt: Five Years of Real Life Experience. Gastroenterology Res 2018;11:138-44. [PMID: 29707081 DOI: 10.14740/gr965w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
143 Choi YJ, Kim HS, Lee SH, Park JS, Nam HS, Kim HJ, Kim CJ, Jeong DJ, Park KS, Baek KA. Evaluation of peptide nucleic acid array for the detection of hepatitis B virus mutations associated with antiviral resistance. Arch Virol 2011;156:1517-24. [PMID: 21594598 DOI: 10.1007/s00705-011-1019-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
144 Soriano V, Nuñez M, Sheldon J, Ramos B, Garcia-Samaniego J, Martín-Carbonero L, Maida I, Gonzalez-Lahoz J. Complications in treating chronic hepatitis B in patients with HIV. Expert Opin Pharmacother 2005;6:2831-42. [PMID: 16318434 DOI: 10.1517/14656566.6.16.2831] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
145 Kim BK, Kwon SY, Lee CH, Choe WH, Choi HM, Koo HW. Analysis of the cost-effectiveness of antiviral therapies in chronic hepatitis B patients in Korea. Korean J Hepatol 2009;15:25. [DOI: 10.3350/kjhep.2009.15.1.25] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
146 Brunelle MN, Lucifora J, Neyts J, Villet S, Holy A, Trepo C, Zoulim F. In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. Antimicrob Agents Chemother. 2007;51:2240-2243. [PMID: 17371827 DOI: 10.1128/aac.01440-06] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
147 Gu EL, Yu YQ, Wang JL, Ji YY, Ma XY, Xie Q, Pan HY, Wu SM, Li J, Chen CW, Xu XW, Wang YE, Yao GB, Wang H, Zhang WH. Response-guided treatment of cirrhotic chronic hepatitis B patients: Multicenter prospective study. World J Gastroenterol 2015; 21(2): 653-660 [PMID: 25605989 DOI: 10.3748/wjg.v21.i2.653] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
148 Villet S, Billioud G, Pichoud C, Lucifora J, Hantz O, Sureau C, Dény P, Zoulim F. In vitro characterization of viral fitness of therapy-resistant hepatitis B variants. Gastroenterology. 2009;136:168-176.e2. [PMID: 18996386 DOI: 10.1053/j.gastro.2008.09.068] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 3.4] [Reference Citation Analysis]
149 Wiegand J, Mössner J, Tillmann H. Diagnostik und Therapie der chronischen Hepatitis B und C. Internist 2008;49:817-32. [DOI: 10.1007/s00108-008-2146-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
150 Kurashige N, Ohkawa K, Hiramatsu N, Yakushijin T, Mochizuki K, Oze T, Kiso S, Kanto T, Takehara T, Kasahara A, Doi Y, Yamada A, Fukuda K, Oshita M, Mita E, Fukui H, Nagase T, Yoshihara H, Imai Y, Kato M, Kashihara T, Hayashi N. Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance. J Gastroenterol 2009;44:864-70. [DOI: 10.1007/s00535-009-0076-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
151 Kuwahara R, Kumashiro R, Ide T, Koga Y, Hino T, Hisamochi A, Tanaka K, Ogata K, Koga H, Takao Y. Predictive factors associated with the progression to hepatic failure caused by lamivudine-resistant HBV. Dig Dis Sci. 2008;53:2999-3006. [PMID: 18618250 DOI: 10.1007/s10620-008-0384-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
152 Leung N. Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol Int 2008;2:163-78. [PMID: 19669301 DOI: 10.1007/s12072-008-9061-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
153 Nogales M, Serrano M, Suárez E, Corpas R, Pérez L, Claro R, Jarana R, Romero-gómez M, Martín-mazuelos E. Determinación del genotipo del virus de la hepatitis B y detección de mutaciones de resistencia al tratamiento con lamivudina. Gastroenterología y Hepatología 2004;27:515-20. [DOI: 10.1016/s0210-5705(03)70518-4] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
154 Karino Y, Toyota J, Kumada H, Katano Y, Izumi N, Kobashi H, Sata M, Moriyama M, Imazeki F, Kage M. Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. Hepatol Int. 2010;4:414-422. [PMID: 20305760 DOI: 10.1007/s12072-009-9162-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
155 Goulis I, Dalekos GN. Entecavir monotherapy for lamivudine-refractory chronic hepatitis B. Expert Rev Anti Infect Ther 2008;6:855-9. [PMID: 19053898 DOI: 10.1586/14787210.6.6.855] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
156 Kim SR, Yang J, Kudo M, Hino O. Recent advances in the management of chronic hepatitis B. Hepat Mon 2011;11:601-11. [PMID: 22140383 DOI: 10.5812/kowsar.1735143x.657] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
157 Koskinas JS, Deutsch M, Adamidi S, Skondra M, Tampaki M, Alexopoulou A, Manolakopoulos S, Pectasides D. The role of tenofovir in preventing and treating hepatitis B virus (HBV) reactivation in immunosuppressed patients. A real life experience from a tertiary center. Eur J Intern Med. 2014;25:768-771. [PMID: 25037900 DOI: 10.1016/j.ejim.2014.06.028] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
158 Huang M, Jie Y, Lin G, Shi H, Li X, Li X, Wu Y, Chong Y. Long-Term Efficacy of Tenofovir Disoproxil Fumarate Therapy in Nucleos(t)ide-Experienced Chronic Hepatitis B Patients. Clin Drug Investig 2016;36:471-8. [PMID: 26992717 DOI: 10.1007/s40261-016-0392-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
159 Liang LB, Chen LL, Chen EQ, Liao J, Tang H. Genotypic resistance profiles in Chinese patients with chronic hepatitis B virus infection and the efficacy of nucleoside analog rescue therapy. Ther Clin Risk Manag 2015;11:417-23. [PMID: 25792840 DOI: 10.2147/TCRM.S78128] [Reference Citation Analysis]
160 Lee SH, Kim HS, Byun IS, Jeong SW, Kim SG, Jang JY, Kim YS, Kim BS. Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy. J Med Virol. 2012;84:217-222. [PMID: 22170540 DOI: 10.1002/jmv.23191] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
161 Nash KL, Alexander GJ. The case for combination antiviral therapy for chronic hepatitis B virus infection. Lancet Infect Dis 2008;8:444-8. [PMID: 18485825 DOI: 10.1016/S1473-3099(08)70102-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
162 Li G, Lin J, Jiang C, Feng Q, Wen L. Trends in chronic hepatitis B treatment-related research from 1973 to 2018: a bibliometric and visual analysis. J Int Med Res 2020;48:300060519893234. [PMID: 31878813 DOI: 10.1177/0300060519893234] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
163 Rivkin AM. Adefovir Dipivoxil in the Treatment of Chronic Hepatitis B. Ann Pharmacother 2004;38:625-33. [DOI: 10.1345/aph.1d362] [Cited by in Crossref: 19] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
164 Fok BS, Gardner S, Piscitelli S, Chen S, Chu TT, Chan JC, Tomlinson B. Pharmacokinetic Properties of Single-Dose Lamivudine/Adefovir Dipivoxil Fixed-Dose Combination in Healthy Chinese Male Volunteers. Clinical Therapeutics 2013;35:68-76. [DOI: 10.1016/j.clinthera.2012.12.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
165 Mitsui F, Tsuge M, Kimura T, Kitamura S, Abe H, Saneto H, Kawaoka T, Miki D, Hatakeyama T, Hiraga N, Imamura M, Kawakami Y, Aikata H, Takahashi S, Hayes CN, Igarashi H, Morimoto K, Shimizu M, Chayama K. Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B. Antimicrob Agents Chemother 2010;54:3205-11. [PMID: 20498322 DOI: 10.1128/AAC.01372-09] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
166 Quer J, Martell M, Rodriguez F, Bosch A, Jardi R, Buti M, Esteban J. The Impact of Rapid Evolution of Hepatitis Viruses. Origin and Evolution of Viruses. Elsevier; 2008. pp. 303-49. [DOI: 10.1016/b978-0-12-374153-0.00015-1] [Cited by in Crossref: 6] [Article Influence: 0.4] [Reference Citation Analysis]
167 Dougherty AM, Guo H, Westby G, Liu Y, Simsek E, Guo JT, Mehta A, Norton P, Gu B, Block T, Cuconati A. A substituted tetrahydro-tetrazolo-pyrimidine is a specific and novel inhibitor of hepatitis B virus surface antigen secretion. Antimicrob Agents Chemother 2007;51:4427-37. [PMID: 17875990 DOI: 10.1128/AAC.00541-07] [Cited by in Crossref: 69] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
168 Karayiannis P. Current therapies for chronic hepatitis B virus infection. Expert Rev Anti Infect Ther. 2004;2:745-760. [PMID: 15482237 DOI: 10.1586/14789072.2.5.745] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
169 Zhang ZH, Wu CC, Chen XW, Li X, Li J, Lu MJ. Genetic variation of hepatitis B virus and its significance for pathogenesis. World J Gastroenterol 2016; 22(1): 126-144 [PMID: 26755865 DOI: 10.3748/wjg.v22.i1.126] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 49] [Article Influence: 10.0] [Reference Citation Analysis]
170 Xia Z, He L, Xiong L, Wen T. The comparison of different antiviral therapies on the prognosis of hepatitis B virus-related hepatocellular carcinoma after curative treatments: A network meta-analysis. Medicine (Baltimore) 2020;99:e20877. [PMID: 32871973 DOI: 10.1097/MD.0000000000020877] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
171 Sun L, Yu J, Zhao Y, Kang P, Li S. Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure: Prognostic factors in lamivudine in ACLF. Journal of Gastroenterology and Hepatology 2010;25:583-90. [DOI: 10.1111/j.1440-1746.2009.06089.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 4.8] [Reference Citation Analysis]
172 He XX, Chen T, Lin JS, Chang Y, Ye BX. Inhibition of the replication of hepatitis B virus in vitro by a novel 2,6-diaminopurine analog, beta-LPA. Biochem Biophys Res Commun 2008;369:513-8. [PMID: 18284916 DOI: 10.1016/j.bbrc.2008.02.039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
173 Pourkarim MR, Amini-Bavil-Olyaee S, Verbeeck J, Lemey P, Zeller M, Rahman M, Maes P, Nevens F, Van Ranst M. Molecular evolutionary analysis and mutational pattern of full-length genomes of hepatitis B virus isolated from Belgian patients with different clinical manifestations. J Med Virol 2010;82:379-89. [PMID: 20087936 DOI: 10.1002/jmv.21726] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
174 Jacquard AC, Brunelle MN, Pichoud C, Durantel D, Carrouée-Durantel S, Trepo C, Zoulim F. In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2’,3’-dideoxy-3’-fluoroguanosine. Antimicrob Agents Chemother. 2006;50:955-961. [PMID: 16495257 DOI: 10.1128/aac.50.3.955-961.2006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
175 Alam S, Azam G, Mustafa G, Ahmad N, Islam B, Podder PK, Khan M. Pretreatment and on-treatment predictors of viral breakthrough in lamivudine therapy for chronic hepatitis B. Hepatol Int 2008;2:494-7. [PMID: 19669325 DOI: 10.1007/s12072-008-9095-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
176 Yim HJ, Seo YS, Yoon EL, Kim CW, Lee CD, Park SH, Lee MS, Park CK, Chae HB, Kim MY. Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial. Liver Int. 2013;33:244-254. [PMID: 23295056 DOI: 10.1111/liv.12036] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
177 Mahabadi M, Norouzi M, Alavian SM, Samimirad K, Azad TM, Saberfar E, Mahmoodi M, Ramezani F, Karimzadeh H, Malekzadeh R. Drug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-naïve chronic HBV patients. Hepat Mon. 2013;13:e6712. [PMID: 23596461 DOI: 10.5812/hepatmon.6712] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
178 Leemans W, Janssen H, de Man R. Future prospectives for the management of chronic hepatitis B. World J Gastroenterol 2007; 13(18): 2554-2567 [PMID: 17552002 DOI: 10.3748/wjg.v13.i18.2554] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 22] [Article Influence: 1.1] [Reference Citation Analysis]
179 Jourdain G, Ngo-Giang-Huong N, Khamduang W. Current progress in the prevention of mother-to-child transmission of hepatitis B and resulting clinical and programmatic implications. Infect Drug Resist 2019;12:977-87. [PMID: 31118703 DOI: 10.2147/IDR.S171695] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
180 Guo J, Li Q, Shi X, Zhang D, Zeng A, Feng T, Huang A. Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naïve patient. Antiviral Research 2009;81:180-3. [DOI: 10.1016/j.antiviral.2008.09.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
181 Kwon SY, Choe WH, Lee CH, Yeon JE, Byun KS. Rapid re-emergence of YMDD mutation of hepatitis B virus with hepatic decompensation after lamivudine retreatment. World J Gastroenterol 2008; 14(27): 4416-4419 [PMID: 18666338 DOI: 10.3748/wjg.14.4416] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
182 Michalak TI, Zhang H, Churchill ND, Larsson T, Johansson NG, Oberg B. Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis B. Antimicrob Agents Chemother. 2009;53:3803-3814. [PMID: 19564357 DOI: 10.1128/aac.00263-09] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
183 Ohrui H, Kohgo S, Hayakawa H, Kodama E, Matsuoka M, Nakata T, Mitsuya H. 2'-deoxy-4'-C-ethynyl-2-fluoroadenosine: a nucleoside reverse transcriptase inhibitor with highly potent activity against wide spectrum of HIV-1 strains, favorable toxic profiles, and stability in plasma. Nucleosides Nucleotides Nucleic Acids 2007;26:1543-6. [PMID: 18066823 DOI: 10.1080/15257770701545218] [Cited by in F6Publishing: 32] [Reference Citation Analysis]
184 Ren P, Cao Z, Mo R, Liu Y, Chen L, Li Z, Zhou T, Lu J, Liu Y, Guo Q, Chen R, Zhou H, Xiang X, Cai W, Wang H, Bao S, Xu Y, Gui H, Xie Q. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk. Expert Opin Biol Ther 2018;18:1085-94. [PMID: 30182763 DOI: 10.1080/14712598.2018.1518423] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
185 Margeridon-Thermet S, Shafer RW. Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. Viruses. 2010;2:2696-2739. [PMID: 21243082 DOI: 10.3390/v2122696] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
186 Zoulim F, Poynard T, Degos F, Slama A, El Hasnaoui A, Blin P, Mercier F, Deny P, Landais P, Parvaz P, Trepo C; Lamivir Study Group. A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. J Viral Hepat. 2006;13:278-288. [PMID: 16611195 DOI: 10.1111/j.1365-2893.2005.00712.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 3.4] [Reference Citation Analysis]
187 Delaney WE, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, Miller MD, Xiong S. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol. 2003;77:11833-11841. [PMID: 14557667 DOI: 10.1128/jvi.77.21.11833-11841.2003] [Cited by in Crossref: 182] [Cited by in F6Publishing: 69] [Article Influence: 9.6] [Reference Citation Analysis]
188 Son CY, Ryu HJ, Lee JM, Ahn SH, Kim DY, Lee MH, Han KH, Chon CY, Park JY. Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir. Liver Int 2012;32:1179-85. [DOI: 10.1111/j.1478-3231.2012.02793.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
189 Hermans LE, Svicher V, Pas SD, Salpini R, Alvarez M, Ben Ari Z, Boland G, Bruzzone B, Coppola N, Seguin-Devaux C, Dyda T, Garcia F, Kaiser R, Köse S, Krarup H, Lazarevic I, Lunar MM, Maylin S, Micheli V, Mor O, Paraschiv S, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Simon F, Stanojevic M, Stene-Johansen K, Tihic N, Trimoulet P, Verheyen J, Vince A, Weis N, Yalcinkaya T, Lepej SZ, Perno C, Boucher CA, Wensing AM; HEPVIR Working Group of the European Society for Translational Antiviral Research. Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE). J Infect Dis 2016;213:39-48. [PMID: 26136470 DOI: 10.1093/infdis/jiv363] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
190 Bang KB, Kim HJ. Management of antiviral drug resistance in chronic hepatitis B. World J Gastroenterol 2014; 20(33): 11641-11649 [PMID: 25206270 DOI: 10.3748/wjg.v20.i33.11641] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
191 Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology. 2008;48:99-108. [PMID: 18537189 DOI: 10.1002/hep.22323] [Cited by in Crossref: 122] [Cited by in F6Publishing: 110] [Article Influence: 8.7] [Reference Citation Analysis]
192 Peters MG, Hann H, Martin P, Heathcote E, Buggisch P, Rubin R, Bourliere M, Kowdley K, Trepo C, Gray D, Sullivan M, Kleber K, Ebrahimi R, Xiong S, Brosgart CL. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ). Gastroenterology 2004;126:91-101. [DOI: 10.1053/j.gastro.2003.10.051] [Cited by in Crossref: 406] [Cited by in F6Publishing: 356] [Article Influence: 22.6] [Reference Citation Analysis]
193 Cho SW, Koh KH, Cheong JY, Lee MH, Hong SP, Yoo WD, Kim S. Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance. Journal of Viral Hepatitis 2010;17:171-7. [DOI: 10.1111/j.1365-2893.2009.01161.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
194 Zoulim F, Lucifora J. Hepatitis B virus drug resistance: mechanism and clinical implications for the prevention of treatment failure. Future Virology 2006;1:361-76. [DOI: 10.2217/17460794.1.3.361] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
195 Tacke F, Gehrke C, Luedde T, Heim A, Manns MP, Trautwein C. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants. J Virol 2004;78:8524-35. [PMID: 15280461 DOI: 10.1128/JVI.78.16.8524-8535.2004] [Cited by in Crossref: 84] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
196 Kim IK, Kim BG, Kim W, Kim D, Kim YJ, Yoon JH, Lee HS. Clinical prediction of failure of Lamivudine prophylaxis for hepatitis B virus-infected patients undergoing cytotoxic chemotherapy for malignancy. Antimicrob Agents Chemother 2012;56:5511-9. [PMID: 22890764 DOI: 10.1128/AAC.00821-12] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
197 Crossan C, Tsochatzis EA, Longworth L, Gurusamy K, Davidson B, Rodríguez-Perálvarez M, Mantzoukis K, O’Brien J, Thalassinos E, Papastergiou V. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technol Assess. 2015;19:1-409, v-vi. [PMID: 25633908 DOI: 10.3310/hta19090] [Cited by in Crossref: 84] [Cited by in F6Publishing: 83] [Article Influence: 12.0] [Reference Citation Analysis]
198 Zoulim F, Buti M, Lok AS. Antiviral-resistant hepatitis B virus: can we prevent this monster from growing? J Viral Hepat. 2007;14 Suppl 1:29-36. [PMID: 17958640 DOI: 10.1111/j.1365-2893.2007.00915.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
199 Chang ML, Chien RN, Yeh CT, Liaw YF. Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B. J Hepatol. 2005;43:72-77. [PMID: 15896869 DOI: 10.1016/j.jhep.2005.02.021] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
200 Yokosuka O, Takaguchi K, Fujioka S, Shindo M, Chayama K, Kobashi H, Hayashi N, Sato C, Kiyosawa K, Tanikawa K. Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection. J Hepatol. 2010;52:791-799. [PMID: 20409606 DOI: 10.1016/j.jhep.2009.12.036] [Cited by in Crossref: 87] [Cited by in F6Publishing: 88] [Article Influence: 7.3] [Reference Citation Analysis]
201 Robinson DM, Scott LJ, Plosker GL. Entecavir: a review of its use in chronic hepatitis B. Drugs. 2006;66:1605-122; discussion 1605-122;. [PMID: 16956310 DOI: 10.2165/00003495-200666120-00009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
202 Sokal EM, Kelly DA, Mizerski J, Badia IB, Areias JA, Schwarz KB, Vegnente A, Little NR, Gardener SD, Jonas MM. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology 2006;43:225-32. [DOI: 10.1002/hep.21020] [Cited by in Crossref: 107] [Cited by in F6Publishing: 78] [Article Influence: 6.7] [Reference Citation Analysis]
203 Nguyen T, Desmond P, Locarnini S. The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatol Int. 2009;3:5-15. [PMID: 19763714 DOI: 10.1007/s12072-009-9149-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
204 Ogawa E, Furusyo N, Murata M, Ohnishi H, Toyoda K, Taniai H, Ihara T, Ikezaki H, Hayashi T, Kainuma M. Longitudinal assessment of liver stiffness by transient elastography for chronic hepatitis B patients treated with nucleoside analog. Hepatol Res. 2011;41:1178-1188. [PMID: 21917085 DOI: 10.1111/j.1872-034x.2011.00869.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
205 Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C, Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 2006;44:1656-65. [DOI: 10.1002/hep.21422] [Cited by in Crossref: 270] [Cited by in F6Publishing: 239] [Article Influence: 16.9] [Reference Citation Analysis]
206 Wang K, Tan W, Tang Y, Deng G. Numerical diagnoses of superinfection in chronic hepatitis B viral dynamics. Intervirology 2011;54:349-56. [PMID: 21242660 DOI: 10.1159/000321454] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
207 Zhu Y, Curtis M, Snow-Lampart A, Yang H, Delaney W, Miller MD, Borroto-Esoda K. In vitro drug susceptibility analysis of hepatitis B virus clinical quasispecies populations. J Clin Microbiol. 2007;45:3335-3341. [PMID: 17687019 DOI: 10.1128/JCM.00272-07] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
208 Durantel D, Carrou�e-durantel S, Werle-lapostolle B, Brunelle M, Pichoud C, Tr�po C, Zoulim F. A new strategy for studyingin vitro the drug susceptibility of clinical isolates of human hepatitis B virus. Hepatology 2004;40:855-64. [DOI: 10.1002/hep.20388] [Cited by in Crossref: 77] [Cited by in F6Publishing: 75] [Article Influence: 4.3] [Reference Citation Analysis]
209 Lee YS, Chung YH, Kim JA, Kim SE, Shin JW, Kim KM, Lim YS, Park NH, Lee HC, Lee YS. Hepatitis B virus with the rtL80V/I mutation is associated with a poor response to adefovir dipivoxil therapy. Liver Int. 2009;29:552-556. [PMID: 19323782 DOI: 10.1111/j.1478-3231.2008.01882.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
210 Cha CK, Kwon HC, Cheong JY, Cho SW, Hong SP, Kim SO, Yoo WD. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B. J Med Virol 2009;81:417-24. [PMID: 19152409 DOI: 10.1002/jmv.21402] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
211 Poordad F, Chee GM. Viral resistance in hepatitis B: prevalence and management. Curr Gastroenterol Rep 2010;12:62-9. [PMID: 20425486 DOI: 10.1007/s11894-009-0088-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
212 Dai CY, Chuang WL, Hsieh MY, Lee LP, Huang JF, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B. Antiviral Res. 2007;75:146-151. [PMID: 17400303 DOI: 10.1016/j.antiviral.2007.02.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
213 Jeon JW, Shin HP, Lee JI, Joo KR, Cha JM, Park JJ, Lim JU, Lim K, Kim S. Efficacy of entecavir and adefovir combination therapy for patients with lamivudine- and entecavir-resistant chronic hepatitis B. Dig Dis Sci. 2012;57:1358-1365. [PMID: 22134785 DOI: 10.1007/s10620-011-1988-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
214 Tsubota A, Arase Y, Suzuki F, Kobayashi M, Matsuda M, Sato J, Suzuki Y, Akuta N, Sezaki H, Hosaka T. Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B. J Med Virol. 2004;73:7-12. [PMID: 15042641 DOI: 10.1002/jmv.20055] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
215 Lin C, Gates CA, Rao BG, Brennan DL, Fulghum JR, Luong YP, Frantz JD, Lin K, Ma S, Wei YY. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem. 2005;280:36784-36791. [PMID: 16087668 DOI: 10.1074/jbc.m506462200] [Cited by in Crossref: 168] [Cited by in F6Publishing: 59] [Article Influence: 9.9] [Reference Citation Analysis]
216 Kobashi H, Fujioka S, Kawaguchi M, Kumada H, Yokosuka O, Hayashi N, Suzuki K, Okanoue T, Sata M, Tsubouchi H, Sato C, Kiyosawa K, Tanikawa K, Seriu T, Ishikawa H, Takaki A, Iwasaki Y, Osawa T, Takaki T, Sakaguchi K, Shiratori Y, Yamamoto K, Tenney DJ, Omata M. Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B. Hepatol Int 2009;3:403-10. [PMID: 19669367 DOI: 10.1007/s12072-008-9108-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
217 Lacey L, Chien R, Chuang W, Pwu R. Economic evaluation of chronic hepatitis B treatments in Taiwan. J Gastroenterol Hepatol 2008;23:571-9. [DOI: 10.1111/j.1440-1746.2008.05360.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
218 Zöllner B, Petersen J, Puchhammer-Stöckl E, Kletzmayr J, Sterneck M, Fischer L, Schröter M, Laufs R, Feucht HH. Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology. 2004;39:42-50. [PMID: 14752821 DOI: 10.1002/hep.20016] [Cited by in Crossref: 79] [Cited by in F6Publishing: 82] [Article Influence: 4.4] [Reference Citation Analysis]
219 Pallier C, Castéra L, Soulier A, Hézode C, Nordmann P, Dhumeaux D, Pawlotsky JM. Dynamics of hepatitis B virus resistance to lamivudine. J Virol. 2006;80:643-653. [PMID: 16378967 DOI: 10.1128/JVI.80.2.643-653.2006] [Cited by in Crossref: 71] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
220 Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, Zhang SL, Qiao FY, Campbell F, Chang CN, Gardner S, Atkins M. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat. 2009;16:94-103. [PMID: 19175878 DOI: 10.1111/j.1365-2893.2008.01056.x] [Cited by in Crossref: 259] [Cited by in F6Publishing: 238] [Article Influence: 18.5] [Reference Citation Analysis]
221 Ailioaie LM, Litscher G. Curcumin and Photobiomodulation in Chronic Viral Hepatitis and Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E7150. [PMID: 32998270 DOI: 10.3390/ijms21197150] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
222 Yatsuji H, Hiraga N, Mori N, Hatakeyama T, Tsuge M, Imamura M, Takahashi S, Fujimoto Y, Ochi H, Abe H. Successful treatment of an entecavir-resistant hepatitis B virus variant. J Med Virol. 2007;79:1811-1817. [PMID: 17935165 DOI: 10.1002/jmv.20981] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
223 Kim V, Abreu RM, Nakagawa DM, Baldassare RM, Carrilho FJ, Ono SK. Pegylated interferon alfa for chronic hepatitis B: systematic review and meta-analysis. J Viral Hepat. 2016;23:154-169. [PMID: 25967226 DOI: 10.1111/jvh.12418] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
224 Lee GH, Inoue M, Toh JK, Chong RH, Aung MO, Koay ES, Lim SG. Two-step evolution of the hepatitis B drug-resistant mutations in a patient who developed primary entecavir resistance. Liver Int 2013;33:642-6. [PMID: 23346997 DOI: 10.1111/liv.12104] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
225 Zhao P, Wang C, Huang L, Xu D, Li T. Comparison of rescue strategies in lamivudine-resistant patients with chronic hepatitis B. Antiviral Res. 2012;96:100-104. [PMID: 22960601 DOI: 10.1016/j.antiviral.2012.08.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
226 Sheldon J, Rodès B, Zoulim F, Bartholomeusz A, Soriano V. Mutations affecting the replication capacity of the hepatitis B virus. J Viral Hepat 2006;13:427-34. [PMID: 16792535 DOI: 10.1111/j.1365-2893.2005.00713.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 82] [Article Influence: 5.6] [Reference Citation Analysis]
227 Villeneuve JP, Durantel D, Durantel S, Westland C, Xiong S, Brosgart CL, Gibbs CS, Parvaz P, Werle B, Trépo C. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol. 2003;39:1085-1089. [PMID: 14642631 DOI: 10.1016/j.jhep.2003.09.022] [Cited by in Crossref: 226] [Cited by in F6Publishing: 213] [Article Influence: 12.6] [Reference Citation Analysis]
228 Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol. 2008;48 Suppl 1:S2-S19. [PMID: 18304680 DOI: 10.1016/j.jhep.2008.01.011] [Cited by in Crossref: 107] [Cited by in F6Publishing: 106] [Article Influence: 7.6] [Reference Citation Analysis]
229 Liaw YF. The current management of HBV drug resistance. J Clin Virol. 2005;34 Suppl 1:S143-S146. [PMID: 16461216 DOI: 10.1016/s1386-6532(05)80025-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
230 Wong GL, Chan HL. Predictors of treatment response in chronic hepatitis B. Drugs. 2009;69:2167-2177. [PMID: 19852523 DOI: 10.2165/11319850-000000000-00000] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
231 Toy M, Onder FO, Idilman R, Kabacam G, Richardus JH, Bozdayi M, Akdogan M, Kuloglu Z, Kansu A, Schalm S, Yurdaydin C. The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country. Eur J Health Econ 2012;13:663-76. [PMID: 22815098 DOI: 10.1007/s10198-012-0413-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
232 Ma J, Zhang Y, Chen X, Jin Y, Chen D, Wu Y, Cui J, Wang H, Liu J, Li N, Gao F. Association of preexisting drug-resistance mutations and treatment failure in hepatitis B patients. PLoS One 2013;8:e67606. [PMID: 23935839 DOI: 10.1371/journal.pone.0067606] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
233 Hung H, Chen H. Cost-Effectiveness Analysis of Prophylactic Lamivudine Use in Preventing Vertical Transmission of Hepatitis B Virus Infection: . PharmacoEconomics 2011;29:1063-73. [DOI: 10.2165/11586470-000000000-00000] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
234 Pessôa MG, Gazzard B, Huang AK, Brandão-mello CE, Cassetti I, Mendes-corrêa MC, Soriano V, Phiri P, Hall A, Brett-smith H. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy. AIDS 2008;22:1779-87. [DOI: 10.1097/qad.0b013e32830b3ab5] [Cited by in Crossref: 35] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
235 Feld JJ, Colledge D, Sozzi V, Edwards R, Littlejohn M, Locarnini SA. The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. Antiviral Res 2007;76:168-77. [PMID: 17709147 DOI: 10.1016/j.antiviral.2007.06.014] [Cited by in Crossref: 118] [Cited by in F6Publishing: 105] [Article Influence: 7.9] [Reference Citation Analysis]
236 Yuen MF, Chow DH, Tsui K, Wong BC, Yuen JC, Wong DK, Lai CL. Liver histology of Asian patients with chronic hepatitis B on prolonged lamivudine therapy. Aliment Pharmacol Ther. 2005;21:841-849. [PMID: 15801919 DOI: 10.1111/j.1365-2036.2005.02410.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
237 Gouskos T, Wightman F, Lewin SR, Torresi J. Highly reproducible transient transfections for the study of hepatitis B virus replication based on an internal GFP reporter system. Journal of Virological Methods 2004;121:65-72. [DOI: 10.1016/j.jviromet.2004.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
238 Borroto-Esoda K, Miller MD, Arterburn S. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepatol. 2007;47:492-498. [PMID: 17692425 DOI: 10.1016/j.jhep.2007.06.011] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 3.3] [Reference Citation Analysis]
239 Thermet A, Buronfosse T, Werle-Lapostolle B, Chevallier M, Pradat P, Trepo C, Zoulim F, Cova L. DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection. J Gen Virol. 2008;89:1192-1201. [PMID: 18420797 DOI: 10.1099/vir.0.83583-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
240 Kang L, Pan J, Wu J, Hu J, Sun Q, Tang J. Anti-HBV Drugs: Progress, Unmet Needs, and New Hope. Viruses. 2015;7:4960-4977. [PMID: 26389937 DOI: 10.3390/v7092854] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
241 Kim HN, Scott J, Cent A, Cook L, Morrow RA, Richardson B, Tapia K, Jerome KR, Lule G, John-Stewart G, Chung MH. HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya. J Viral Hepat 2011;18:e447-52. [PMID: 21914062 DOI: 10.1111/j.1365-2893.2011.01466.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
242 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2016;22:18-75. [PMID: 27044762 DOI: 10.3350/cmh.2016.22.1.18] [Cited by in Crossref: 115] [Cited by in F6Publishing: 126] [Article Influence: 19.2] [Reference Citation Analysis]
243 Shaikh T, Cooper C. Reassessing the role for lamivudine in chronic hepatitis B infection: a four-year cohort analysis. Can J Gastroenterol 2012;26:148-50. [PMID: 22408765 DOI: 10.1155/2012/936259] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
244 Kim JH, Ko SY, Choe WH, Kwon SY, Lee CH. Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients. Clin Mol Hepatol. 2013;19:273-279. [PMID: 24133665 DOI: 10.3350/cmh.2013.19.3.273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
245 Maynard M, Parvaz P, Durantel S, Chevallier M, Chevallier P, Lot M, Trepo C, Zoulim F. Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure. J Hepatol. 2005;42:279-281. [PMID: 15664258 DOI: 10.1016/j.jhep.2004.09.017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 1.8] [Reference Citation Analysis]
246 Bailly F, Zoulim F. [Treatment of hepatitis B. Therapeutic management]. Gastroenterol Clin Biol 2008;32:S172-8. [PMID: 18472238 DOI: 10.1016/j.gcb.2008.04.008] [Reference Citation Analysis]
247 Pawlotsky JM, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, Locarnini S, Martin P, Richman DD, Zoulim F. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: Recommendations for a standardized approach. Gastroenterology. 2008;134:405-415. [PMID: 18242209 DOI: 10.1053/j.gastro.2007.11.036] [Cited by in Crossref: 163] [Cited by in F6Publishing: 151] [Article Influence: 10.9] [Reference Citation Analysis]
248 Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531-561. [PMID: 26201469 DOI: 10.1007/s12072-012-9365-4] [Cited by in Crossref: 695] [Cited by in F6Publishing: 660] [Article Influence: 69.5] [Reference Citation Analysis]
249 Idilman R, Cinar K, Seven G, Bozkus Y, Elhan A, Bozdayi M, Yurdaydin C, Bahar K. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients. J Viral Hepat. 2012;19:220-226. [PMID: 22329377 DOI: 10.1111/j.1365-2893.2011.01542.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
250 Li D, Cheng H, Gong W, Jiang Y, Liang P, Zhang J. Detection of primary YMDD mutations in HBV-related hepatocellular carcinoma using hybridization-fluorescence polarization. J Virol Methods. 2013;187:259-263. [PMID: 23178585 DOI: 10.1016/j.jviromet.2012.11.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
251 Ko SY, Oh HB, Park CW, Lee HC, Lee JE. Analysis of hepatitis B virus drug-resistant mutant haplotypes by ultra-deep pyrosequencing. Clin Microbiol Infect. 2012;18:E404-E411. [PMID: 22757653 DOI: 10.1111/j.1469-0691.2012.03951.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
252 Kim YJ, Kim BG, Jung JO, Yoon JH, Lee HS. High rates of progressive hepatic functional deterioration whether lamivudine therapy is continued or discontinued after emergence of a lamivudine-resistant mutant: a prospective randomized controlled study. J Gastroenterol 2006;41:240-9. [PMID: 16699858 DOI: 10.1007/s00535-005-1750-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
253 Fan H, Li R, Gu Y, Si D, Liu C. Quantitation of bentysrepinine (Y101) in rat plasma by liquid chromatography tandem mass spectrometry: Application to pharmacokinetic study. Journal of Chromatography B 2012;889-890:103-9. [DOI: 10.1016/j.jchromb.2012.02.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
254 Matsuura K, Tanaka Y, Kusakabe A, Hige S, Inoue J, Komatsu M, Kuramitsu T, Hirano K, Ohno T, Hasegawa I, Kobashi H, Hino K, Hiasa Y, Nomura H, Sugauchi F, Nojiri S, Joh T, Mizokami M. Recommendation of lamivudine-to-entecavir switching treatment in chronic hepatitis B responders: Randomized controlled trial: LAM-to-ETV switching treatment. Hepatology Research 2011;41:505-11. [DOI: 10.1111/j.1872-034x.2011.00807.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
255 Tsubota A. How do naturally occurring YMDD-motif mutants influence the clinical course of lamivudine-naïve patients with chronic hepatitis B virus infection? J Gastroenterol Hepatol 2006;21:1769-71. [PMID: 17074012 DOI: 10.1111/j.1440-1746.2006.04768.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
256 Beloukas A, Geretti AM. Hepatitis B Virus Drug Resistance. In: Mayers DL, Sobel JD, Ouellette M, Kaye KS, Marchaim D, editors. Antimicrobial Drug Resistance. Cham: Springer International Publishing; 2017. pp. 1227-42. [DOI: 10.1007/978-3-319-47266-9_26] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
257 Athamneh RY, Arıkan A, Sayan M, Mahafzah A, Sallam M. Variable Proportions of Phylogenetic Clustering and Low Levels of Antiviral Drug Resistance among the Major HBV Sub-Genotypes in the Middle East and North Africa. Pathogens 2021;10:1333. [PMID: 34684283 DOI: 10.3390/pathogens10101333] [Reference Citation Analysis]
258 Ryu HJ, Lee JM, Ahn SH, Kim do Y, Lee MH, Han KH, Chon CY, Park JY. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. J Med Virol. 2010;82:1835-1842. [PMID: 20872709 DOI: 10.1002/jmv.21898] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 3.6] [Reference Citation Analysis]
259 Ohishi W, Chayama K. Treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol Res. 2012;42:219-225. [PMID: 22176139 DOI: 10.1111/j.1872-034x.2011.00921.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
260 Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009;49:1503-14. [DOI: 10.1002/hep.22841] [Cited by in Crossref: 564] [Cited by in F6Publishing: 524] [Article Influence: 43.4] [Reference Citation Analysis]
261 Thompson AJV, Ayres A, Yuen L, Bartholomeusz A, Bowden DS, Iser DM, Chen RYM, Demediuk B, Shaw G, Bell SJ, Watson KJR, Locarnini SA, Desmond PV. Lamivudine resistance in patients with chronic hepatitis B: Role of clinical and virological factors. J Gastroenterol Hepatol 2007;22:1078-85. [DOI: 10.1111/j.1440-1746.2006.04630.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
262 Choi K, Lee HM, Jun BG, Lee SH, Kim HS, Kim SG, Kim YS, Kim BS, Jeong SW, Jang JY, Kim YD, Cheon GJ. [Efficacy of tenofovir-based rescue therapy for patients with drug-resistant chronic hepatitis B]. Korean J Gastroenterol 2015;65:35-42. [PMID: 25603852 DOI: 10.4166/kjg.2015.65.1.35] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
263 Sede M, Ojeda D, Cassino L, Westergaard G, Vazquez M, Benetti S, Fay F, Tanno H, Quarleri J. Long-term monitoring drug resistance by ultra-deep pyrosequencing in a chronic hepatitis B virus (HBV)-infected patient exposed to several unsuccessful therapy schemes. Antiviral Res. 2012;94:184-187. [PMID: 22453135 DOI: 10.1016/j.antiviral.2012.03.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
264 Yatsuji H, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, Takahashi S, Iwao E, Fujimoto Y, Ochi H. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob Agents Chemother. 2006;50:3867-3874. [PMID: 16982790 DOI: 10.1128/aac.00239-06] [Cited by in Crossref: 51] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
265 Zoulim F. Antiviral therapy of chronic hepatitis B. Antiviral Res. 2006;71:206-215. [PMID: 16716414 DOI: 10.1016/j.antiviral.2006.04.003] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 3.3] [Reference Citation Analysis]
266 Perrillo RP. Therapy of hepatitis B — Viral suppression or eradication? Hepatology 2006;43:S182-93. [DOI: 10.1002/hep.20970] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
267 Zoulim F, Parvaz P, Marcellin P, Zarski J, Beaugrand M, Benhamou Y, Bailly F, Maynard M, Trepo C, Trylesinski A, Monchecourt F; the VIRESPA study group. Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure. Liver International 2009;29:420-6. [DOI: 10.1111/j.1478-3231.2008.01867.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
268 Kumar M, Sarin SK. Systematic review: combination therapies for treatment-naïve chronic hepatitis B. Aliment Pharmacol Ther. 2008;27:1187-1209. [PMID: 18373730 DOI: 10.1111/j.1365-2036.2008.03695.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
269 Reijnders JG, LA Janssen H. New approaches in the management of chronic hepatitis B: role of tenofovir. Infect Drug Resist 2009;2:13-26. [PMID: 21694884 DOI: 10.2147/idr.s3918] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
270 Lai CL, Lim SG, Brown NA, Zhou XJ, Lloyd DM, Lee YM, Yuen MF, Chao GC, Myers MW. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology. 2004;40:719-726. [PMID: 15349912 DOI: 10.1002/hep.20374] [Cited by in Crossref: 74] [Cited by in F6Publishing: 64] [Article Influence: 4.1] [Reference Citation Analysis]
271 Ismail AM, Samuel P, Ramachandran J, Eapen CE, Kannangai R, Abraham P. Lamivudine Monotherapy in Chronic Hepatitis B Patients from the Indian Subcontinent: Antiviral Resistance Mutations and Predictive Factors of Treatment Response. Mol Diagn Ther 2014;18:63-71. [DOI: 10.1007/s40291-013-0054-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
272 Zoulim F. [New virologic tests and their application in management of chronic hepatitis B]. Presse Med 2006;35:317-26. [PMID: 16493336 DOI: 10.1016/s0755-4982(06)74577-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
273 Ding X, Yang J, Wang S. Antisense Oligonucleotides Targeting Abhydrolase Domain Containing 2 Block Human Hepatitis B Virus Propagation. Oligonucleotides 2011;21:77-84. [DOI: 10.1089/oli.2011.0280] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
274 Zhu Y, Curtis M, Qi X, Miller MD, Borroto-Esoda K. Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues. Antivir Chem Chemother 2009;19:165-76. [PMID: 19374144 DOI: 10.1177/095632020901900404] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
275 Njei B, Kumar S, Kongnyuy EJ; Cochrane Hepato-Biliary Group. Adefovir dipivoxil for chronic hepatitis B. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd009521] [Cited by in Crossref: 5] [Article Influence: 0.5] [Reference Citation Analysis]
276 Njei B, Garg SK, Kenta-bibi E, Zhao P, Kongnyuy EJ; Cochrane Hepato-Biliary Group. Isoprinosine versus other antiviral drugs for chronic hepatitis B. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd010506] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
277 Benhamou Y, Thibault V, Vig P, Calvez V, Marcelin AG, Fievet MH, Currie G, Chang CG, Biao L, Xiong S. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol. 2006;44:62-67. [PMID: 16274835 DOI: 10.1016/j.jhep.2005.08.020] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 3.1] [Reference Citation Analysis]
278 Perrillo R, Nair S. Hepatitis B. Zakim and Boyer's Hepatology. Elsevier; 2006. pp. 635-63. [DOI: 10.1016/b978-1-4160-3258-8.50036-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
279 Núñez M, Soriano V. Management of patients co-infected with hepatitis B virus and HIV. Lancet Infect Dis 2005;5:374-82. [PMID: 15919623 DOI: 10.1016/S1473-3099(05)70141-9] [Cited by in Crossref: 46] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
280 Santos SA, Uriel AJ, Park JS, Lucas J, Carriero D, Jaffe D, Dieterich DT. Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen: . European Journal of Gastroenterology & Hepatology 2006;18:1247-53. [DOI: 10.1097/01.meg.0000243877.17444.5e] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
281 Zoulim F, Locarnini S. Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. Liver Int 2013;33:116-24. [DOI: 10.1111/liv.12069] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 5.3] [Reference Citation Analysis]
282 Koukoulioti E, Brodzinski A, Mihm U, Sarrazin C, Jung M, Schott E, Fülöp B, Schlosser B, Berg T, van Bömmel F. Risk factors for resistance development against lamivudine during long-term treatment of chronic hepatitis B virus infections. European Journal of Gastroenterology & Hepatology 2019;31:845-52. [DOI: 10.1097/meg.0000000000001351] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
283 Uchiyama M, Tamai Y, Ikeda T. Entecavir as prophylaxis against hepatitis B virus reactivation following chemotherapy for lymphoma. Int J Infect Dis 2010;14:e265-6. [PMID: 19665406 DOI: 10.1016/j.ijid.2009.04.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
284 Yao G, Chen C, Lu W, Ren H, Tan D, Wang Y, Xu D, Liu J, Xu D, Llamoso C. Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naïve Chinese patients with chronic hepatitis B: a randomized, multicenter study. Hepatol Int. 2008;2:486-493. [PMID: 19669324 DOI: 10.1007/s12072-008-9088-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
285 Zoulim F. Treatment of pre- and post-liver transplantation HBV infection: Should we aim at combination therapy? Hepatology. 2003;38:1353-1355. [PMID: 14647043 DOI: 10.1016/j.hep.2003.10.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
286 Valaydon ZS, Locarnini SA. The virological aspects of hepatitis B. Best Practice & Research Clinical Gastroenterology 2017;31:257-64. [DOI: 10.1016/j.bpg.2017.04.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
287 Li Y, Kan ZC, Han T. Lamivudine therapy after transcatheter arterial chemoembolization for patients with Hepatocellular carcinoma complicated by hepatitis B virus: an analysis of 30 cases. Shijie Huaren Xiaohua Zazhi 2008; 16(15): 1700-1703 [DOI: 10.11569/wcjd.v16.i15.1700] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
288 Lee S. Use of TNF Inhibitor in Particular Clinical Settings. J Korean Rheum Assoc 2009;16:264. [DOI: 10.4078/jkra.2009.16.4.264] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
289 Manns MP, Akarca US, Chang TT, Sievert W, Yoon SK, Tsai N, Min A, Pangerl A, Beebe S, Yu M, Wongcharatrawee S. Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. Expert Opin Drug Saf. 2012;11:361-368. [PMID: 22233350 DOI: 10.1517/14740338.2012.653340] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
290 Zeng M, Mao Y, Yao G, Wang H, Hou J, Wang Y, Ji BN, Chang CN, Barker KF. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology 2006;44:108-16. [PMID: 16799983 DOI: 10.1002/hep.21225] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 3.3] [Reference Citation Analysis]
291 Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother. 2004;48:3498-3507. [PMID: 15328117 DOI: 10.1128/aac.48.9.3498-3507.2004] [Cited by in Crossref: 407] [Cited by in F6Publishing: 120] [Article Influence: 22.6] [Reference Citation Analysis]
292 Lazarevic I. Clinical implications of hepatitis B virus mutations: Recent advances. World J Gastroenterol 2014; 20(24): 7653-7664 [PMID: 24976703 DOI: 10.3748/wjg.v20.i24.7653] [Cited by in CrossRef: 82] [Cited by in F6Publishing: 81] [Article Influence: 10.3] [Reference Citation Analysis]
293 Chan TM, Tse KC, Tang CSO, Lai KN, Ho SKN. Prospective Study on Lamivudine-Resistant Hepatitis B in Renal Allograft Recipients. Am J Transplant 2004;4:1103-9. [DOI: 10.1111/j.1600-6143.2004.00467.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
294 Sheldon J, Sarmento E Castro R, Soriano V. [Resistance in hepatitis B virus]. Enferm Infecc Microbiol Clin 2008;26 Suppl 7:49-55. [PMID: 19100231 DOI: 10.1016/s0213-005x(08)76519-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
295 Kozielewicz D, Halota W, Wietlicka-Piszcz M. Tenofovir rescue therapy in chronic hepatitis B patients who failed previous nucleoside analogue treatment. Hepatol Int 2016;10:302-9. [PMID: 26612013 DOI: 10.1007/s12072-015-9681-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
296 Coffin CS, Fung SK, Ma MM; Canadian Association for the Study of the Liver. Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol 2012;26:917-38. [PMID: 23248795 DOI: 10.1155/2012/506819] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
297 Lupo J, Larrat S, Hilleret MN, Germi R, Boyer V, Nicod S, Barguès G, Leroy V, Seigneurin JM, Zarski JP, Morand P. Assessment of selective real-time PCR for quantitation of lamivudine and adefovir hepatitis B virus-resistant strains and comparison with direct sequencing and line probe assays. J Virol Methods 2009;156:52-8. [PMID: 19041345 DOI: 10.1016/j.jviromet.2008.10.028] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
298 Tsai WL, Sun WC, Cheng JS. Chronic Hepatitis B with Spontaneous Severe Acute Exacerbation. Int J Mol Sci. 2015;16:28126-28145. [PMID: 26703566 DOI: 10.3390/ijms161226087] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
299 Xu X, Huang P, Tian H, Chen Y, Ge N, Tang W, Yang B, Xia J. Role of lamivudine with transarterial chemoembolization in the survival of patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2014;29:1273-8. [PMID: 24955456 DOI: 10.1111/jgh.12554] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
300 Bermingham SL, Hughes R, Fenu E, Sawyer LM, Boxall E, T Kennedy P, Dusheiko G, Hill-Cawthorne G, Thomas H. Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom. Value Health 2015;18:800-9. [PMID: 26409607 DOI: 10.1016/j.jval.2015.05.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
301 Conca P, Riccio A, Tarantino G. Successful Lamivudine Monotherapy in an Elderly Patient Suffering from HBV-Related Decompensated Cirrhosis Associated with Widespread Leukocytoclastic Vasculitis. Int J Immunopathol Pharmacol 2009;22:531-5. [DOI: 10.1177/039463200902200231] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
302 Kim J, Lee SH, Kim HS, Choi K, Jeong SW, Kim SG, Jang JY, Kim YS, Kim BS. Long-term outcomes and dynamics of mutants associated with lamivudine-adefovir rescue therapy in patients with lamivudine-resistant chronic hepatitis B. Gut Liver 2015;9:103-8. [PMID: 25287170 DOI: 10.5009/gnl14018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
303 Hann HW, Gregory VL, Dixon JS, Barker KF. A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B: Lamivudine resistance. Hepatol Int. 2008;2:440-456. [PMID: 19669319 DOI: 10.1007/s12072-008-9105] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
304 Marrone A, Zampino R, Karayannis P, Cirillo G, Cesaro G, Guerrera B, Ricciotti R, del Giudice EM, Utili R, Adinolfi LE, Ruggiero G. Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis. Aliment Pharmacol Ther 2005;22:707-14. [PMID: 16197491 DOI: 10.1111/j.1365-2036.2005.02653.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
305 Shimizu Y, Hiraoka A, Yamago H, Shiraishi A, Imai Y, Tatsukawa H, Tanihira T, Miyata H, Ninomiya T, Tokumoto Y. Hypophosphatemia in patients with hepatitis B virus infection undergoing long-term adefovir dipivoxil therapy. Hepatol Res. 2014;44:1081-1087. [PMID: 24033734 DOI: 10.1111/hepr.12226] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
306 Lavocat F, Dény P, Pichoud C, Al Hawajri N, Kitrinos K, Borroto-esoda K, Zoulim F. Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy. Journal of Hepatology 2013;59:684-95. [DOI: 10.1016/j.jhep.2013.05.038] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
307 Kim HS, Yim HJ, Jang MK, Park JW, Suh SJ, Seo YS, Kim JH, Kim BH, Park SJ, Lee SH, Kim SG, Kim YS, Lee JI, Lee JW, Kim IH, Kim TY, Kim JW, Jeong SH, Jung YK, Park H, Group SGHOBOARS. Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies. World J Gastroenterol 2015; 21(38): 10874-10882 [PMID: 26478678 DOI: 10.3748/wjg.v21.i38.10874] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
308 Qian Z, Jianqiong W, Hongmei L, Rong Z, Li L, Jinping Z, Tao S. Distribution and epidemiologic trends of HBV genotypes and subtypes in 14 countries neighboring china. Hepat Mon 2015;15:e24422. [PMID: 26045702 DOI: 10.5812/hepatmon.15(5)2015.24422] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
309 Cohen Stuart JW, Velema M, Schuurman R, Boucher CA, Hoepelman AI. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J Med Virol. 2009;81:441-445. [PMID: 19152397 DOI: 10.1002/jmv.21422] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 4.1] [Reference Citation Analysis]
310 Gao S, Duan ZP, Coffin CS. Clinical relevance of hepatitis B virus variants. World J Hepatol 2015; 7(8): 1086-1096 [PMID: 26052397 DOI: 10.4254/wjh.v7.i8.1086] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
311 Sablon E, Shapiro F. Advances in Molecular Diagnosis of HBV Infection and Drug Resistance. Int J Med Sci. 2005;2:8-16. [PMID: 15968334 DOI: 10.7150/ijms.2.8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
312 Zoulim F. Assessment of treatment efficacy in HBV infection and disease. J Hepatol 2006;44:S95-9. [PMID: 16352365 DOI: 10.1016/j.jhep.2005.11.020] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
313 Zoulim F, Durantel D, Deny P. Management and prevention of drug resistance in chronic hepatitis B. Liver Int. 2009;29 Suppl 1:108-115. [PMID: 19207973 DOI: 10.1111/j.1478-3231.2008.01939.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
314 Locarnini S, Omata M. Molecular virology of hepatitis B virus and the development of antiviral drug resistance. Liver International 2006;26:11-22. [DOI: 10.1111/j.1478-3231.2006.01371.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
315 Dakin H, Sherman M, Fung S, Fidler C, Bentley A. Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective. Pharmacoeconomics 2011;29:1075-91. [PMID: 22077579 DOI: 10.2165/11589260-000000000-00000] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
316 Liu Z, Jiang L, Liang G, Song E, Jiang W, Zheng Y, Gong C. Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta-analysis of prophylaxis management. J Viral Hepat 2017;24:561-72. [PMID: 28072494 DOI: 10.1111/jvh.12672] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
317 Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet. 2003;362:2089-2094. [PMID: 14697813 DOI: 10.1016/s0140-6736(03)15108-2] [Cited by in Crossref: 563] [Cited by in F6Publishing: 198] [Article Influence: 31.3] [Reference Citation Analysis]
318 Ohrui H. 2′-deoxy′4′-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, is highly potent against all human immunodeficiency viruses type 1 and has low toxicity. Chem Record 2006;6:133-43. [DOI: 10.1002/tcr.20078] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
319 Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, Hussain M, Lok AS. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol. 2006;44:283-290. [PMID: 16338024 DOI: 10.1016/j.jhep.2005.10.018] [Cited by in Crossref: 247] [Cited by in F6Publishing: 210] [Article Influence: 14.5] [Reference Citation Analysis]
320 Zhou HY, Luo Y, Chen WD, Gong GZ. Hepatitis B virus mutation may play a role in hepatocellular carcinoma recurrence: A systematic review and meta-regression analysis. J Gastroenterol Hepatol. 2015;30:977-983. [PMID: 25689418 DOI: 10.1111/jgh.12917] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
321 Bai YJ, Zhao JR, Lv GT, Zhang WH, Wang Y, Yan XJ. Rapid and high throughput detection of HBV YMDD mutants with fluorescence polarization. World J Gastroenterol 2003; 9(10): 2344-2347 [PMID: 14562408 DOI: 10.3748/wjg.v9.i10.2344] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
322 Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Niinomi T, Yasuda S, Andou Y, Yamamoto K, Tanaka J. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. J Hepatol. 2013;58:427-433. [PMID: 23123221 DOI: 10.1016/j.jhep.2012.10.025] [Cited by in Crossref: 95] [Cited by in F6Publishing: 90] [Article Influence: 9.5] [Reference Citation Analysis]
323 Sinn DH, Lee HI, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. Virological response to adefovir monotherapy and the risk of adefovir resistance. World J Gastroenterol 2011; 17(30): 3526-3530 [PMID: 21941420 DOI: 10.3748/wjg.v17.i30.3526] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
324 ACT-HBV Asia Pacific Steering Committee Members. Chronic hepatitis B: treatment alert. Liver Int. 2006;26:47-58. [PMID: 18473475 DOI: 10.1111/j.1478-3231.2006.01374.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
325 Yatsuji H, Suzuki F, Sezaki H, Akuta N, Suzuki Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Watahiki S, Iwasaki S, Kobayashi M, Kumada H. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: Two-year follow-up. Journal of Hepatology 2008;48:923-31. [DOI: 10.1016/j.jhep.2008.02.019] [Cited by in Crossref: 79] [Cited by in F6Publishing: 68] [Article Influence: 5.6] [Reference Citation Analysis]
326 Kanada A, Takehara T, Ohkawa K, Kato M, Tatsumi T, Miyagi T, Sakamori R, Yamaguchi S, Uemura A, Kohga K. Early emergence of entecavir-resistant hepatitis B virus in a patient with hepatitis B virus/human immunodeficiency virus coinfection. Hepatol Res. 2008;38:622-628. [PMID: 18070052 DOI: 10.1111/j.1872-034x.2007.00307.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
327 Sun S, Li Y, Liu B, Zhang B, Han S, Li X. Establishment of stable cell lines in which the HBV genome replicates episomally for evaluation of antivirals. Arch Med Sci 2020;16:407-13. [PMID: 32190152 DOI: 10.5114/aoms.2018.79712] [Reference Citation Analysis]
328 Congly SE, Brahmania M. Variable access to antiviral treatment of chronic hepatitis B in Canada: a descriptive study. CMAJ Open 2019;7:E182-9. [PMID: 30926602 DOI: 10.9778/cmajo.20180108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
329 Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trépo C, Zoulim F. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol. 2007;46:531-538. [PMID: 17239478 DOI: 10.1016/j.jhep.2006.11.016] [Cited by in Crossref: 117] [Cited by in F6Publishing: 114] [Article Influence: 7.3] [Reference Citation Analysis]
330 Meng T, Shi X, Gong X, Deng H, Huang Y, Shan X, Shan Y, Huang A, Long Q. Analysis of the prevalence of drug-resistant hepatitis B virus in patients with antiviral therapy failure in a Chinese tertiary referral liver centre (2010-2014). J Glob Antimicrob Resist 2017;8:74-81. [PMID: 28017671 DOI: 10.1016/j.jgar.2016.10.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
331 Pawlotsky JM. Is hepatitis virus resistance to antiviral drugs a threat? Gastroenterology 2012;142:1369-72. [PMID: 22537445 DOI: 10.1053/j.gastro.2011.12.060] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
332 Elefsiniotis I, Buti M, Jardi R, Vezali E, Esteban R. Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance. Eur J Intern Med. 2009;20:478-481. [PMID: 19712848 DOI: 10.1016/j.ejim.2008.12.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
333 King LK, Lee A, Anandacoomarasamy A. Use of biological disease-modifying anti-rheumatic drugs in patients with concurrent rheumatic disease and hepatitis B. Intern Med J 2012;42:523-31. [PMID: 21790927 DOI: 10.1111/j.1445-5994.2011.02569.x] [Reference Citation Analysis]
334 Kao JH. Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol Int. 2007;1:415-430. [PMID: 19669337 DOI: 10.1007/s12072-007-9033-2] [Cited by in Crossref: 67] [Cited by in F6Publishing: 74] [Article Influence: 4.5] [Reference Citation Analysis]
335 Nash K. Telbivudine in the treatment of chronic hepatitis B. Adv Ther 2009;26:155-69. [PMID: 19225726 DOI: 10.1007/s12325-009-0004-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
336 Deng X, Li Q, Guo J. Dynamics of lamivudine-resistant hepatitis B virus strains in patients with entecavir rescue therapy. Virus Genes 2013;47:1-9. [DOI: 10.1007/s11262-013-0915-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
337 Jung YK, Yeon JE, Han WS, Kim JH, Kim JH, Park JJ, Kim JS, Bak YT, Yoo W, Hong SP, Kim SO, Kwon SY, Byun KS, Lee CH. Virologic response at 12 months of treatment predicts sustained antiviral efficacy in patients with adefovir-treated Lamivudine-resistant chronic hepatitis B. Gut Liver 2010;4:212-8. [PMID: 20559524 DOI: 10.5009/gnl.2010.4.2.212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
338 Strasfeld L, Chou S. Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin North Am 2010;24:413-37. [PMID: 20466277 DOI: 10.1016/j.idc.2010.01.001] [Cited by in Crossref: 74] [Cited by in F6Publishing: 55] [Article Influence: 6.2] [Reference Citation Analysis]
339 Bloom K, Ely A, Arbuthnot P. Recent advances in use of gene therapy to treat hepatitis B virus infection. Adv Exp Med Biol. 2015;848:31-49. [PMID: 25757614 DOI: 10.1007/978-1-4939-2432-5_2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
340 Kurashige N, Hiramatsu N, Ohkawa K, Yakushijin T, Kiso S, Kanto T, Takehara T, Kasahara A, Doi Y, Yamada A, Oshita M, Mita E, Hagiwara H, Nagase T, Yoshihara H, Hayashi E, Imai Y, Kato M, Kashihara T, Hayashi N. Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B. J Gastroenterol 2009;44:601-7. [PMID: 19387534 DOI: 10.1007/s00535-009-0038-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
341 Zoulim F. Entecavir: a new treatment option for chronic hepatitis B. J Clin Virol. 2006;36:8-12. [PMID: 16515882 DOI: 10.1016/j.jcv.2006.01.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
342 Liu Y, Fung S, Gane EJ, Dinh P, Flaherty JF, Svarovskaia ES, Miller MD, Kitrinos KM. Evaluation of HBV DNA decay kinetics in patients containing both rtM204V/I mutant and wild-type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)/TDF. J Med Virol 2014;86:1473-81. [PMID: 24861361 DOI: 10.1002/jmv.23982] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
343 França P, Coelho H, Brandão C, Segadas J, Quintaes R, Carrilho F, Ono-nita S, Mattos A, Tovo C, Gouvea V, Sablon E, Vanderborght B. The emergence of YMDD mutants precedes biochemical flare by 19 weeks in lamivudine-treated chronic hepatitis B patients: an opportunity for therapy reevaluation. Braz J Med Biol Res 2007;40:1605-14. [DOI: 10.1590/s0100-879x2006005000169] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
344 Baldick CJ, Eggers BJ, Fang J, Levine SM, Pokornowski KA, Rose RE, Yu CF, Tenney DJ, Colonno RJ. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. J Hepatol. 2008;48:895-902. [PMID: 18362040 DOI: 10.1016/j.jhep.2007.12.024] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 3.4] [Reference Citation Analysis]
345 Pérez V. Viral hepatitis: historical perspectives from the 20th to the 21st century. Arch Med Res. 2007;38:593-605. [PMID: 17613350 DOI: 10.1016/j.arcmed.2006.09.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
346 Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, Boron-Kaczmarska A, Martin P, Goodman Z, Colonno R. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology. 2006;130:2039-2049. [PMID: 16762627 DOI: 10.1053/j.gastro.2006.04.007] [Cited by in Crossref: 306] [Cited by in F6Publishing: 273] [Article Influence: 19.1] [Reference Citation Analysis]
347 Chien RN, Liaw YF. Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success. Best Pract Res Clin Gastroenterol 2008;22:1081-92. [PMID: 19187868 DOI: 10.1016/j.bpg.2008.11.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
348 Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125:1714-1722. [PMID: 14724824 DOI: 10.1053/j.gastro.2003.09.033] [Cited by in Crossref: 544] [Cited by in F6Publishing: 507] [Article Influence: 30.2] [Reference Citation Analysis]
349 Wang RS, Zhang H, Zhu YF, Han B, Yang ZJ. Detection of YMDD mutants using universal template real-time PCR. World J Gastroenterol 2006; 12(8): 1308-1311 [PMID: 16534892 DOI: 10.3748/wjg.v12.i8.1308] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
350 Ni Laoi B, Herra C, Norris S, Crowley B. First report of genotypic resistance to adefovir in chronic HBV in the Republic of Ireland. Journal of Antimicrobial Chemotherapy 2006;57:1009-10. [DOI: 10.1093/jac/dkl065] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
351 Lin C, Lin K, Luong YP, Rao BG, Wei YY, Brennan DL, Fulghum JR, Hsiao HM, Ma S, Maxwell JP, Cottrell KM, Perni RB, Gates CA, Kwong AD. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 2004;279:17508-14. [PMID: 14766754 DOI: 10.1074/jbc.M313020200] [Cited by in Crossref: 218] [Cited by in F6Publishing: 69] [Article Influence: 12.1] [Reference Citation Analysis]
352 Liu Y, Xu Z, Wang Y, Li X, Liu L, Chen L, Xin S, Xu D. rtM204Q may serve as a novel lamivudine-resistance-associated mutation of hepatitis B virus. PLoS One. 2014;9:e89015. [PMID: 24586482 DOI: 10.1371/journal.pone.0089015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
353 Yang DH, Xie YJ, Zhao NF, Pan HY, Li MW, Huang HJ. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients. World J Gastroenterol 2015; 21(9): 2746-2753 [PMID: 25759545 DOI: 10.3748/wjg.v21.i9.2746] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
354 Niu CY, Ren TS, Chen X, Cheng BP. Efficacy of immunotherapy using autologous dendritic cells pulsed with hepatitis B surface antigen in patients with chronic hepatitis B. Shijie Huaren Xiaohua Zazhi 2009; 17(25): 2635-2639 [DOI: 10.11569/wcjd.v17.i25.2635] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
355 Wang F, Wang H, Shen H, Meng C, Weng X, Zhang W. Evolution of hepatitis B virus polymerase mutations in a patient with HBeAg-positive chronic hepatitis B virus treated with sequential monotherapy and add-on nucleoside/nucleotide analogues. Clin Ther. 2009;31:360-366. [PMID: 19302908 DOI: 10.1016/j.clinthera.2009.02.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
356 Kim SR, Yang J, Kudo M, Hino O. Recent advances in the management of chronic hepatitis B. Hepat Mon 2011;11:601-11. [PMID: 22140383 DOI: 10.5812/kowsar.1735143x.657] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
357 Suzuki F, Toyoda J, Katano Y, Sata M, Moriyama M, Imazeki F, Kage M, Seriu T, Omata M, Kumada H. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. J Gastroenterol Hepatol. 2008;23:1320-1326. [PMID: 18554238 DOI: 10.1111/j.1440-1746.2008.05455.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
358 Benhamou Y, Fleury H, Trimoulet P, Pellegrin I, Urbinelli R, Katlama C, Rozenbaum W, Le Teuff G, Trylesinski A, Piketty C. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology. 2006;43:548-555. [PMID: 16496322 DOI: 10.1002/hep.21055] [Cited by in Crossref: 115] [Cited by in F6Publishing: 102] [Article Influence: 7.2] [Reference Citation Analysis]
359 Zhang Q, Liao Y, Chen J, Cai B, Su Z, Ying B, Lu X, Tao C, Wang L. Epidemiology study of HBV genotypes and antiviral drug resistance in multi-ethnic regions from Western China. Sci Rep. 2015;5:17413. [PMID: 26612031 DOI: 10.1038/srep17413] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
360 Hann HW, Gregory VL, Dixon JS, Barker KF. A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B : Lamivudine resistance. Hepatol Int 2008;2:440-56. [PMID: 19669319 DOI: 10.1007/s12072-008-9105-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
361 Gupta N, Goyal M, Wu CH, Wu GY. The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs. J Clin Transl Hepatol. 2014;2:202-211. [PMID: 26357626 DOI: 10.14218/jcth.2014.00021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
362 Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology. 2009;49:S174-S184. [PMID: 19399794 DOI: 10.1002/hep.22900] [Cited by in Crossref: 142] [Cited by in F6Publishing: 140] [Article Influence: 10.9] [Reference Citation Analysis]
363 Park H, Park JY, Kim SU, Kim DY, Han KH, Chon CY, Ahn SH. Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir. World J Gastroenterol 2013; 19(43): 7671-7679 [PMID: 24431895 DOI: 10.3748/wjg.v19.i43.7671] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
364 Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009;137:1593-1608.e1-e2. [PMID: 19737565 DOI: 10.1053/j.gastro.2009.08.063] [Cited by in Crossref: 468] [Cited by in F6Publishing: 443] [Article Influence: 36.0] [Reference Citation Analysis]
365 Chae HB, Hann HW. Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine. World J Gastroenterol 2007; 13(30): 4085-4090 [PMID: 17696226 DOI: 10.3748/wjg.v13.i30.4085] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
366 Arrese E, Basaras M, Blanco S, Ruiz P, Cisterna R. Monitoring of therapy in patients with chronic hepatitis B virus. Eur J Gastroenterol Hepatol 2010;22:736-40. [PMID: 19550344 DOI: 10.1097/MEG.0b013e32832e0a44] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
367 Kim IH, Kim SH, Kim HC, Shin KD, Kim SW, Lee SO, Lee ST, Kim DG. [Effect of initial virologic response to adefovir on the development of resistance to adefovir in lamivudine-resistant chronic hepatitis B]. Korean J Hepatol 2007;13:349-62. [PMID: 17898551 DOI: 10.3350/kjhep.2007.13.3.349] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
368 Zhou X, Gao ZW, Meng J, Chen XY, Zhong DF. Effects of ketoconazole and rifampicin on the pharmacokinetics of GLS4, a novel anti-hepatitis B virus compound, in dogs. Acta Pharmacol Sin 2013;34:1420-6. [PMID: 24056704 DOI: 10.1038/aps.2013.76] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
369 Kasırga E. Lamivudine resistance in children with chronic hepatitis B. World J Hepatol 2015; 7(6): 896-902 [PMID: 25937866 DOI: 10.4254/wjh.v7.i6.896] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
370 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2006; 14(19): 1853-1858 [DOI: 10.11569/wcjd.v14.i19.1853] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
371 Revill P, Locarnini S. The Basis for Antiviral Therapy: Drug Targets, Cross-Resistance, and Novel Small Molecule Inhibitors. In: Liaw Y, Zoulim F, editors. Hepatitis B Virus in Human Diseases. Cham: Springer International Publishing; 2016. pp. 303-24. [DOI: 10.1007/978-3-319-22330-8_14] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
372 Chung SW, Chang Y, Lee HY, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ. Is Combination Antiviral Therapy Mandatory for Maintenance Therapy in Fully Suppressed Multidrug-Resistant Hepatitis B Patients? Gastroenterol Res Pract 2018;2018:6948235. [PMID: 30647735 DOI: 10.1155/2018/6948235] [Reference Citation Analysis]
373 Lee YS, Chung YH, Kim JA, Jin YJ, Park WH, Kim SE, Lee D, Shim JH, Kim KM, Lim YS. rtL180M mutation of hepatitis B virus is closely associated with frequent virological resistance to adefovir dipivoxil therapy. J Gastroenterol Hepatol. 2012;27:300-305. [PMID: 21777282 DOI: 10.1111/j.1440-1746.2011.06853.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
374 Cho YK, Cui XJ, Jeong SU, Song BC. Different mechanism of selection of adefovir-resistant mutant viruses during adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B. Antiviral Res 2014;112:8-17. [PMID: 25303802 DOI: 10.1016/j.antiviral.2014.09.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
375 Tacke F, Kroy DC. Treatment for hepatitis B in patients with drug resistance. Ann Transl Med 2016;4:334. [PMID: 27761438 DOI: 10.21037/atm.2016.09.19] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
376 Heipertz RA Jr, Starkey JL, Miller TG, Hu J, Isom HC. trans-Complementation of HBV rtM204I mutant replication by HBV wild-type polymerase. Virology 2009;388:57-67. [PMID: 19383566 DOI: 10.1016/j.virol.2009.03.018] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
377 Luo A, Jiang X, Ren H. Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis. Virol J 2018;15:139. [PMID: 30201035 DOI: 10.1186/s12985-018-1050-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
378 Abbas Z, Siddiqui AR. Management of hepatitis B in developing countries. World J Hepatol 2011; 3(12): 292-299 [PMID: 22216369 DOI: 10.4254/wjh.v3.i12.292] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
379 Song B, Cui XJ, Cho Y, Choi EK, Hyun S, Song HJ, Kim HU. New scoring system for predicting relapse after lamivudine-induced hepatitis B e-antigen loss in chronic hepatitis B patients. Hepatology Research 2009;39:1064-71. [DOI: 10.1111/j.1872-034x.2009.00560.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
380 Mello FC, Lago BV, Lewis-Ximenez LL, Fernandes CA, Gomes SA. Detection of mixed populations of wild-type and YMDD hepatitis B variants by pyrosequencing in acutely and chronically infected patients. BMC Microbiol. 2012;12:96. [PMID: 22672436 DOI: 10.1186/1471-2180-12-96] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
381 Buti M, Elefsiniotis I, Jardi R, Vargas V, Rodriguez-frias F, Schapper M, Bonovas S, Esteban R. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. Journal of Hepatology 2007;47:366-72. [DOI: 10.1016/j.jhep.2007.04.011] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 4.0] [Reference Citation Analysis]
382 Shaw T, Bowden S, Locarnini S. Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy? Gastroenterology. 2004;126:343-347. [PMID: 14699512 DOI: 10.1053/j.gastro.2003.11.022] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
383 Yu H, Liu E, Lu S, Zhao S. Treatment with peginterferon versus interferon in Chinese patients with hepatitis B. Biomedicine & Pharmacotherapy 2010;64:559-64. [DOI: 10.1016/j.biopha.2010.03.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
384 Farrell GC, Teoh NC. Management of chronic hepatitis B virus infection: a new era of disease control. Intern Med J 2006;36:100-13. [PMID: 16472264 DOI: 10.1111/j.1445-5994.2006.01027.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
385 Lee HW, Park JY, Kim BK, Kim MY, Lee JI, Kim YS, Yoon KT, Han KH, Ahn SH. Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study). Clin Mol Hepatol 2016;22:443-9. [PMID: 27880997 DOI: 10.3350/cmh.2016.0037] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
386 Cheng J, Han Y, Jiang JD. Establishment of drug-resistant HBV small-animal models by hydrodynamic injection. Acta Pharm Sin B 2014;4:270-6. [PMID: 26579395 DOI: 10.1016/j.apsb.2014.06.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
387 Gao LL, Wang XY, Lin JS, Zhang YH, Li Y. Efficacies of β-L-D4A against hepatitis B virus in 2.2.15 cells. World J Gastroenterol 2008; 14(8): 1263-1267 [PMID: 18300355 DOI: 10.3748/wjg.14.1263] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
388 Fung SK, Fontana RJ. Management of Drug-Resistant Chronic Hepatitis B. Clinics in Liver Disease 2006;10:275-302. [DOI: 10.1016/j.cld.2006.05.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
389 Ohishi W, Chayama K. Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy. Clin Exp Nephrol 2011;15:634-40. [DOI: 10.1007/s10157-011-0464-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
390 Lee YB, Jung EU, Kim BH, Lee JH, Cho H, Ahn H, Choi WM, Cho YY, Lee M, Yoo JJ. Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B. Antimicrob Agents Chemother. 2015;59:972-978. [PMID: 25421484 DOI: 10.1128/AAC.04454-14] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
391 Hongthanakorn C, Lok AS. New pharmacologic therapies in chronic hepatitis B. Gastroenterol Clin North Am 2010;39:659-80. [PMID: 20951923 DOI: 10.1016/j.gtc.2010.08.012] [Reference Citation Analysis]
392 Huy TT, Abe K. Molecular epidemiology of hepatitis B and C virus infections in Asia. Pediatr Int. 2004;46:223-230. [PMID: 15056256 DOI: 10.1046/j.1442-200x.2004.01867.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 1.7] [Reference Citation Analysis]
393 Liu H, Wan Z, She L, Zhu Y, Cai Z, Wu B, Zhuang Q, Ke P, Wu X, Li Z, Huang X. Inflammation Pharmacological Reaction and YMDD Mutational Patterns in Lamivudine Therapeutics Hepatitis B Virus. Front Pharmacol 2021;12:648170. [PMID: 33935748 DOI: 10.3389/fphar.2021.648170] [Reference Citation Analysis]
394 Ohkawa K, Takehara T, Kato M, Deguchi M, Kagita M, Hikita H, Sasakawa A, Kohga K, Uemura A, Sakamori R, Yamaguchi S, Miyagi T, Ishida H, Tatsumi T, Hayashi N. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus. J Infect Dis 2008;198:1150-8. [PMID: 18713056 DOI: 10.1086/591941] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
395 Malmström S, Hannoun C, Lindh M. Mutation analysis of lamivudine resistant hepatitis B virus strains by TaqMan PCR. J Virol Methods. 2007;143:147-152. [PMID: 17416427 DOI: 10.1016/j.jviromet.2007.03.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
396 Heipertz RA Jr, Miller TG, Kelley CM, Delaney WE 4th, Locarnini SA, Isom HC. In vitro study of the effects of precore and lamivudine-resistant mutations on hepatitis B virus replication. J Virol 2007;81:3068-76. [PMID: 17215289 DOI: 10.1128/JVI.02341-06] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
397 Yamamoto T, Maruyama Y, Ohashi N, Yasuda H, Shinozaki M. Hypophosphatemia predicts a failure to recover from adefovir-related renal injury after dose reduction in lamivudine-resistant hepatitis B patients: P predicts recovery from adefovir renal injury. Hepatol Res 2017;47:1272-81. [DOI: 10.1111/hepr.12865] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
398 Yeon JE, Yoo W, Hong SP, Chang YJ, Yu SK, Kim JH, Seo YS, Chung HJ, Moon MS, Kim SO. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut. 2006;55:1488-1495. [PMID: 16461777 DOI: 10.1136/gut.2005.077099] [Cited by in Crossref: 158] [Cited by in F6Publishing: 144] [Article Influence: 9.9] [Reference Citation Analysis]
399 Özgüler M, Akbulut HH, Akbulut A. Evaluation of Interleukin-10 Levels in Patients Diagnosed with Chronic Hepatitis. West Indian Med J 2015;64:71-5. [PMID: 26360676 DOI: 10.7727/wimj.2014.154] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
400 Lee KS, Kweon YO, Um SH, Kim BH, Lim YS, Paik SW, Heo J, Lee HJ, Kim DJ, Kim TH, Lee YS, Byun KS, Kim D, Lee MS, Yu K, Suh DJ. Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B. Clin Mol Hepatol 2017;23:331-9. [PMID: 28946736 DOI: 10.3350/cmh.2016.0040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
401 Peveling-Oberhag J, Herrmann E, Kronenberger B, Farnik H, Susser S, Sarrazin C, Zeuzem S, Hofmann WP. Dynamics of hepatitis B virus quasispecies heterogeneity and virologic response in patients receiving low-to-moderate genetic barrier nucleoside analogs. J Viral Hepat. 2013;20:234-239. [PMID: 23490367 DOI: 10.1111/jvh.12013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
402 Alberti A, Caporaso N. HBV therapy: guidelines and open issues. Dig Liver Dis. 2011;43 Suppl 1:S57-S63. [PMID: 21195373 DOI: 10.1016/s1590-8658(10)60693-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
403 Rolle CP, Berhe M, Singh T, Ortiz R, Wurapa A, Ramgopal M, Leone PA, Matthews JE, Dalessandro M, Underwood MR, Angelis K, Wynne BR, Merrill D, Nguyen C, van Wyk J, Zolopa AR. Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV. AIDS 2021;35:1957-65. [PMID: 34115650 DOI: 10.1097/QAD.0000000000002979] [Reference Citation Analysis]
404 Abdelnabi Z, Saleh N, Baraghithi S, Glebe D, Azzeh M. Subgenotypes and mutations in the s and polymerase genes of hepatitis B virus carriers in the West Bank, palestine. PLoS One. 2014;9:e113821. [PMID: 25503289 DOI: 10.1371/journal.pone.0113821] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
405 Myers R, Clark C, Khan A, Kellam P, Tedder R. Genotyping Hepatitis B virus from whole- and sub-genomic fragments using position-specific scoring matrices in HBV STAR. J Gen Virol. 2006;87:1459-1464. [PMID: 16690910 DOI: 10.1099/vir.0.81734-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 2.2] [Reference Citation Analysis]
406 Cai Q, Chen K, Chen J, Wu S, Geng Q, Huang H, Lin T, Jiang W, Xia Z, Duan H, Rao H, Yao M, Hu L. The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy. PLoS One 2016;11:e0164210. [PMID: 27711135 DOI: 10.1371/journal.pone.0164210] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
407 Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109-162. [PMID: 22893865 DOI: 10.3350/cmh.2012.18.2.109] [Cited by in Crossref: 109] [Cited by in F6Publishing: 121] [Article Influence: 10.9] [Reference Citation Analysis]
408 Yen RD, Bonatti H, Mendez J, Aranda-michel J, Satyanarayana R, Dickson RC. Case Report of Lamivudine-Resistant Hepatitis B Virus Infection Post Liver Transplantation from a Hepatitis B Core Antibody Donor: De Novo HB Infection from an HB Core Antibody Donor . American Journal of Transplantation 2006;6:1077-83. [DOI: 10.1111/j.1600-6143.2006.01313.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
409 Yuen MF, Fung J, Wong DK, Lai CL. Prevention and management of drug resistance for antihepatitis B treatment. Lancet Infect Dis. 2009;9:256-264. [PMID: 19324298 DOI: 10.1016/s1473-3099(09)70056-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
410 Delaney WE 4th, Ray AS, Yang H, Qi X, Xiong S, Zhu Y, Miller MD. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother. 2006;50:2471-2477. [PMID: 16801428 DOI: 10.1128/aac.00138-06] [Cited by in Crossref: 172] [Cited by in F6Publishing: 70] [Article Influence: 10.8] [Reference Citation Analysis]
411 Cho JH, Cheong JY, Kang JK, Park JS, Lee MH, Lim NK, Hong SP, Kim S, Yoo WD, Cho SW. Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients. Korean J Hepatol 2008;14:58. [DOI: 10.3350/kjhep.2008.14.1.58] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
412 Tillmann HL. Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol 2007; 13(1): 125-140 [PMID: 17206760 DOI: 10.3748/wjg.v13.i1.125] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 54] [Article Influence: 3.7] [Reference Citation Analysis]
413 Yang SS, Cai CW, Ma XQ, Xu J, Yu CB. Efficacy and cost-effectiveness of antiviral regimens for entecavir-resistant hepatitis B: A systematic review and network meta-analysis. Hepatobiliary Pancreat Dis Int 2020;19:507-14. [PMID: 33051132 DOI: 10.1016/j.hbpd.2020.09.007] [Reference Citation Analysis]
414 Pawlotsky JM. The concept of hepatitis B virus mutant escape. J Clin Virol. 2005;34 Suppl 1:S125-S129. [PMID: 16461211 DOI: 10.1016/s1386-6532(05)80021-6] [Cited by in Crossref: 57] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
415 Huang Y, Wu H, Wu S, Fu D, Ma Y, Shen X. A meta-analysis of nucleos(t)ide analogues in patients with decompensated cirrhosis due to hepatitis B. Dig Dis Sci. 2013;58:815-823. [PMID: 23053891 DOI: 10.1007/s10620-012-2414-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
416 Dan YY, Wai CT, Lee YM, Sutedja DS, Seet BL, Lim SG. Outcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhotics. World J Gastroenterol 2005; 11(28): 4344-4350 [PMID: 16038032 DOI: 10.3748/wjg.v11.i28.4344] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
417 Jiang L, Jiang LS, Cheng NS, Yan LN. Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol 2009; 15(20): 2489-2499 [PMID: 19468999 DOI: 10.3748/wjg.15.2489] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
418 Rizzetto M, Tassopoulos NC, Goldin RD, Esteban R, Santantonio T, Heathcote EJ, Lagget M, Taak NK, Woessner MA, Gardner SD. Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2005;42:173-179. [PMID: 15664241 DOI: 10.1016/j.jhep.2004.10.006] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 2.8] [Reference Citation Analysis]
419 Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, Moorat A, Gardner S, Woessner M, Bourne E. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology. 2004;126:81-90. [PMID: 14699490 DOI: 10.1053/j.gastro.2003.10.050] [Cited by in Crossref: 304] [Cited by in F6Publishing: 269] [Article Influence: 16.9] [Reference Citation Analysis]
420 Pardo M, Bartolomé J, Carreño V. Current therapy of chronic hepatitis B. Arch Med Res 2007;38:661-77. [PMID: 17613358 DOI: 10.1016/j.arcmed.2006.12.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
421 Inoue J, Ueno Y, Wakui Y, Niitsuma H, Fukushima K, Yamagiwa Y, Shiina M, Kondo Y, Kakazu E, Tamai K. Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern. J Viral Hepat. 2011;18:206-215. [PMID: 20367795 DOI: 10.1111/j.1365-2893.2010.01301.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
422 Fung J, Lai C, Yuen M. Overcoming the problem of chronic hepatitis B. Drug Discovery Today: Therapeutic Strategies 2006;3:197-202. [DOI: 10.1016/j.ddstr.2006.05.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
423 Devi U, Locarnini S. Role of Resistance Testing During Oral Antiviral Therapy of Chronic Hepatitis B. Curr Hepatitis Rep 2012;11:55-64. [DOI: 10.1007/s11901-012-0132-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
424 Vernet G, Tran N. The DNA-Chip technology as a new molecular tool for the detection of HBV mutants. J Clin Virol. 2005;34 Suppl 1:S49-S53. [PMID: 16461224 DOI: 10.1016/s1386-6532(05)80010-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
425 Patterson SJ, Angus PW. Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues. Curr Opin Organ Transplant 2009;14:225-30. [PMID: 19373086 DOI: 10.1097/MOT.0b013e32832b1f32] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
426 Sun D, Nassal M. Stable HepG2- and Huh7-based human hepatoma cell lines for efficient regulated expression of infectious hepatitis B virus. J Hepatol. 2006;45:636-645. [PMID: 16935386 DOI: 10.1016/j.jhep.2006.05.019] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 4.8] [Reference Citation Analysis]
427 Ikeda F, Baba N, Takaguchi K, Kubota J, Miyoshi K, Fujioka S, Moritou Y, Takeuchi Y, Yasunaka T, Miyake Y, Takaki A, Iwasaki Y, Kobashi H, Yamamoto K. Hepatitis B e antigen predicts delayed reduction of HBV DNA without viral breakthrough with adefovir dipivoxil and lamivudine: a 5-year study of patients with hepatitis B with lamivudine resistance. J Med Virol 2012;84:1562-70. [PMID: 22930504 DOI: 10.1002/jmv.23371] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
428 Ma YX, Song ZW, Teng X, Fu LJ, Hao ML, Chen SJ, Xu WZ, Gu HX. Successful establishment and evaluation of a new animal model for studying the hepatitis B virus YVDD mutant. Arch Virol 2013;158:785-91. [PMID: 23183771 DOI: 10.1007/s00705-012-1550-1] [Reference Citation Analysis]
429 Kim JK, Lee HJ, Lee YJ, Chun JY, Lee IK, Lim YS, Suh DJ, Ko SY, Kim MH, Oh HB. Direct detection of lamivudine-resistant hepatitis B virus mutants by a multiplex PCR using dual-priming oligonucleotide primers. J Virol Methods. 2008;149:76-84. [PMID: 18291537 DOI: 10.1016/j.jviromet.2008.01.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
430 Niesters HG, Pas S, de Man RA. Detection of hepatitis B virus genotypes and mutants: current status. J Clin Virol 2005;34 Suppl 1:S4-8. [PMID: 16461222 DOI: 10.1016/s1386-6532(05)80002-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
431 Sánchez-Quijano A, Lissen E. [Treatment of viral hepatitis (I). Treatment of chronic hepatitis B]. Enferm Infecc Microbiol Clin 2006;24:453-61; quiz 462. [PMID: 16956535 DOI: 10.1157/13091784] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
432 Park JW, Kim HS, Seo DD, Jang JS, Shin WG, Kim KH, Jang MK, Lee JH, Kim HY, Kim DJ. Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance. J Viral Hepat. 2011;18:e475-e481. [PMID: 21914066 DOI: 10.1111/j.1365-2893.2011.01479.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
433 Sheng YJ, Liu JY, Tong SW, Hu HD, Zhang DZ, Hu P, Ren H. Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. Virol J. 2011;8:393. [PMID: 21824397 DOI: 10.1186/1743-422x-8-393] [Cited by in Crossref: 43] [Cited by in F6Publishing: 17] [Article Influence: 3.9] [Reference Citation Analysis]
434 Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trépo C, Zoulim F. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol. 2008;48:747-755. [PMID: 18331765 DOI: 10.1016/j.jhep.2008.01.027] [Cited by in Crossref: 143] [Cited by in F6Publishing: 141] [Article Influence: 10.2] [Reference Citation Analysis]